

SUBJECT INDEX TO VOLUME 12

Abnormal cannabidiol receptor	1387	indirect approaches towards	1687
Abused drugs	2610	inflammation in	1140
Acetoxylated xanthenes	2513	markers for	1689
Acridine conjugated PNAs	2589	neurotrophins in	1144
Active agents	821	NGF peptidomimetics in	1144
lung volume in	839	non-steroidal anti-inflammatory drugs in ..	1140,1687
Acute coronary syndromes (ACS)	445	novel approaches towards	1677
Acyclic 5-FU <i>O,N</i> -acetals	1436	oxidative stress in	1141
antiproliferative activities of	1436	PET-diagnostics for	1677
apoptosis induction by	1436	role of amyloid-	1138
Adamantyl PNA conjugates	2589	role of cholinesterase inhibitors	1143
Adenine	2101	role of TAU	1142
IR spectra of	2101	role of α -secretase	1679
A_3 Adenosine receptors	1325	role of β -secretase	1683
in tumors	1325	senile plaques in	1138
A_3 Adenosine receptor antagonists	1320	α -secretase inhibitors in	1679
in cancer diagnosis	1326	β -secretase inhibitors in	1684
in cancer therapy	1326	statins in	1140
α -Adrenoceptor antagonists	935	therapeutic opportunities in	1137
β -Adrenoceptors	2057	therapies for	1677
<i>in vivo</i>	2057	vaccination in	1687
non-invasive molecular imaging of	2057	AMG 548	2979
potency of	2059	Amine-boranes	1995
role of PET-radioligands	2057	and metal complexes	1996
Adriamycin	2607	as antineoplastic agents	1996
inhibits oxidative phosphorylation	2607	as anti-osteoporotic agents	2008
2-AG 1416		as antiviral agents	2002
biosynthesis of	1416	as dopamine receptor antagonists	2008
degradation of	1416	as hypolipidemic agents	2002
Aging	2619	as P2Y ₁ receptor agonists	2008
AHL-based inhibitors	3105	pharmacological activities of	1995
Albumin	759	synthesis of	1995
non-covalent binding of small molecule		Amino acids	476,478,2860
chelates to	759	constraining side-chain groups of	476
Aldehydes	2613	differences of orientation in	2860
Alkylating agents	2611	interacting with TCR	2860
Allosteric inhibitors	1290	methylation of	478
Allo-transplantation	1921	<i>N</i> -alkylation of	478
implications for	1921	with constrained torsion angles	478
Altered peptide ligands (APLs)	1526	<i>O</i> -Aminoalkyloxime group	2343
against multiple sclerosis	1526	as substitute for unsaturated γ -butyrolactone	
Aluminum	2776	moiety	2343
Alzheimer's disease (AD)	1137, 1677	discovery of	2343
antioxidants in	1141	(<i>S</i>)-2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)	
chelators in	1688	propionic acid (AMPA)	617
cholesterol in	1140	antagonism of	619
copper in	1688	mechanism for agonism of	619
drug development for	1677	structure activity relationship (SAR) of	620
glutamate-mediated excitotoxicity in	1142	2-Amino-4-phenylpyrimidines (FXR)	1061
hormonal approaches in	1141	medicinal chemistry of	1061
		pharmacology of	1061
		Aminocoumarin antibiotics	419
		biological activities of	426
		by inactivation of methyltransferases	421
		by modification of 3-acyl groups using	
		chemoenzymatic synthesis	423
		form genetically engineered streptomyces	

strains	419	Anthrax toxins	667
from mutasynthesis experiments	424	as biological warfare agent	682
generation of	421	development of potential inhibitors of	684
isolation of	420	mechanism of action of	683
structural elucidation of	420	medicinal chemistry of	667
2-Aminoquinoxalin-4-ones (LXR)	1068	signs/symptoms of	683
medicinal chemistry of	1068	Anti-atherosclerotic agents	1755
pharmacology of	1069	antioxidants as	1764
Aminotetralins	1722	cholesterol transport inhibitors as	1760
Aminothiazoles (FXR)	1059	fibrates as	1767
medicinal chemistry of	1059	inhibition of acyl coenzyme A as	1762
pharmacology of	1061	inhibitors of intestinal epithelial uptake of bile	
Amphipilic transdermal permeation enhancers	2273	acids as	1762
as skin permeation enhancers	2276	matrix metalloproteinases inhibitors as	1768
interaction with intercellular lipids	2276	new trends in	1755
interaction with protein structures	2277	PPAR ligands as	1767
mechanism of action of	2276	statins as	1757
structure-activity relationships of	2273	Antibiotics	1697
<i>via</i> skin barrier	2273	engineering of	1697
<i>via</i> stratum corneum	2274	plasticity of streptomyces genome-evolution	
Analgesic agents	2006	of	1697
aliphatic amine-boranes as	2006	Anticancer platinum complexes	2075
thiocholines as	2007	analytical approaches of	2075
base-boronated 2'-deoxynucleosides as	2008	capillary electrophoresis (CE) of	2090
boron-containing peptides as	2007	CE-MS of	2090
cholines as	2007	DNA-binding modes of	2086
heteroboranes as	2008	in clinical evaluation	2077
heterocyclic amine-boranes as	2007	in tumor tissue	2082
phosphine boranes as	2007	novel design strategies of	2075
Anandamide	1414	oxaliplatin analogues as	2088
biosynthesis of	1414	preclinical situation of	2075
degradation of	1415	screening of	2089
formation by consecutive actions of PLA ₂	1420	solid phase assays of	2090
Androgen antagonists	928	solid phase/high-throughput synthesis of	2089
Androgen receptor modulators	1037	with biologically active ligands	2088
cross-reactivity to other NRs	1050	Anticholinergic/ -blocking antedugs	2236
medicinal chemistry of	1048	Antifolates	197,2251
pharmacology of	1050	structure-based drug design of.....	197
Anesthetics	841	Antigenic epitopes	1501
metabolism of	841	physiologically important domains in	
other drugs for	841	proximity to	1501
retention of	841	Anti-inflammatory	2006
Angiotensin	351	aliphatic amine-boranes as	2006
structural studies of.....	351	base-boronated 2'-deoxynucleosides as	2008
substrate selectivity of.....	351	boron-containing peptides as	2007
Annexin V/IZ-VAD-FMK	791	cholines as	2007
measurement of apoptosis using	791	heteroboranes as	2008
Anorectum	257	heterocyclic amine-boranes as	2007
anatomy of.....	257	phosphine boranes as	2007
physiology of.....	257	thiocholines as	2007
Ansabananin	2117	Anti-inflammatory drugs	2927,2963
synthesis of	2117	caspase-1	2963
Antedugs	2227	inhibitors of TACE as	2963
antipsoriatic metalloprotein inhibiting		limitations with	2927
antedurgs as	2237	Antimalarials	2650
Anthralin	2613	development of resistance against	2650
		recently discovered potent	2650

Antimalarial activity	2545	spectral/gravimetric analysis of	2097
of xanthone-cyclamines	2545	synthesis of	2097
Antimalarial agents	2547	Antischizophrenic agents	560
naturally-occurring xanthenes as	2547	Antisense oligonucleotides	71,73,2193
Antimalarial drugs	2539	mechanism of action of.....	71
drug resistance of	2539	therapeutic applications of.....	73
Anti-mRNA strategies	2194	Anti-snake venom plants	2627
activation of RNase H by	2196	bioactivity of	2627
application of	2206	coumestans against	2634
as antibacterial agents	2207	diterpenes against	2638
as anticancer agents	2208	flavonoids against	2634
cellular/ <i>in vivo</i> delivery of	2209	nitro-compounds against	2635
clinical trials of	2210	other phenolic compounds against	2637
immunostimulatory side effects of	2209	phenolic compounds against	2634
in apoptosis	2207	pterocarpanes against	2634
in cardiovascular therapeutics	2208	steroids against	2638
in CNS therapeutics	2208	terpenoids compounds against	2638
in inflammation therapeutics	2208	triterpenes against	2638
mechanism of action of	2196	Anti-STAT 1 compounds	1823
medicinal chemistry of	2199	in animal/human models of inflammation- associated pathologies	1825
modifications of	2199	Anti-tuberculosis agents	1873
pharmacokinetics of	2205	advances in	1873
protein half-life of	2209	structural classes of	1873
toxicity of	2205	acetamides as	1874
translational arrest by blocking ribosome by	2196	5-arylidene-2-thiohydantoins as	1874
Antimycin A	2609	benzoxazoles as	1874
Antineoplastic activity	1998	benzothiazoles as	1874
of 3'-aminocyanoborane-2',3'-dideoxypyrimidines	2001	benzoic acid hydrazones as	1874
of base-boronated adenosine ribo/ arabinonucleosides	2001	benzoxazines as	1875
of carboxy/cyanoborane adducts of cyclohexylamines/toluidines	1998	carbohydrates as	1875
of cyanoborane adducts of 2'-deoxynucleosides	1999	chalcones as	1877
of cyanoborane adducts of N ⁶ -benzoyladenine/6- triphenylphosphonylpurine	2001	chalcones like compounds as	1877
of cyanoborane and carboxyborane adducts of tricyclohexyl/triphenylphosphine	1998	coumarins as	1877
of di/tripeptides	1997	deazapteridines as	1877
of heterocyclic amine-boranes	1998	imidazole ring containing compounds as	1877
of N ² -isobutryl-2'-deoxyguanosine-N ⁷ - cyanoboranes	2001	indoloquinazolinones as	1878
of oligonucleotides of thymidine bases	2002	isothiosemicarbazones as	1878
of sodium diethylphosphite-carboxyborane/ related derivatives	1998	mycobactins as	1879
of thymidine nucleotide analogues	2002	1,8-naphthyridines as	1879
Antioxidant enzymes	2616	phenazines as	1879
Antioxidants	1170,2619,2731	purines as	1879
effects of	2731	pyridines as	1880
Antiretroviral compounds	1705	<i>N</i> -pyridinylsalicylamides as	1880
Anti-sars-coronavirus test compounds	2097	pyrimidines as	1881
infrared (IR) absorption spectroscopy data of	2101	thymidines as	1881
gradient-selected HMBC (gs-HMBC) 2D ¹ H NMR/ ¹³ C NMR spectroscopy of	2100	pyrroles as	1881
proton nuclear magnetic resonance (¹ H NMR) spectroscopy of	2099	quinolines as	1881
quantitative UV spectrophotometry of	2097,2102	quinoxalines as	1883
		terpenes as	1883
		thiadiazine thiones as	1883
		thiolactomycin analogs as	1884
		toluidines as	1884
		trizzoles as	1884
		Antitumoral drugs	127
		DNA-intercalators as.....	127
		search of.....	127
		Antiviral nucleic acid binder	2114
		synthesis of	2114

Aotus monkey immunogenetics	2855	cellular activity of	1537
Apoptosis	2619	B cell toleragens for treating	1892
Aporphines	1731	treatment of	1537
Apototic agents	2218	Autoimmunity	1495
signal transduction pathway for	2218	other anti-basement membrane-related	1501
Arginine mimetic subunits.....	54	Azado/azado base	2118
Aromatic amino acids	516	synthesis of	2118
analysis of metabolites of	516	Azapeptides	589
Aromatic peptide nucleic acids	2578	antagonists of	591
Aroylhydrazone	2717	as pharmacological agents	589
Arsenic	1189,2607,2777	biological action of	590
effect on glutathione	1193	conformational properties of	589
effect on level of lipid peroxidation	2607	receptor agonists of	591
effect on membrane lipids	1192	synthesis of	589
effect on proteins	1192	AZOGALL	2121
in cancer treatment	1194	synthesis of	2121
induced oxidative damage to DNA	1191	B cell receptor	1888
induced regulation of transcription factors	1190	effect of hapten-polymer conjugates	1889
toxicity of	1193	role in activation	1888
Artificial carriers	1470	suppression by	1888
2-Aryl-2-hydroxy-4-methyl-2-trifluorome-		Bacterial peptide deformylase	1608
thylpentanoylamines	1034	<i>in vivo</i> active PDF inhibitors	1614
cross-reactivity to other NRs	1034	PDF inhibitors with antibacterial activity	
medicinal chemistry of	1034	against	1613
pharmacology of	1036	P ₁ -P _{1'} scissile bond site at	1616
Arylamine <i>N</i> -acetyltransferases (NAT).....	311	source of	1608
and drug response.....	311	structure of	1608
cancer risk of.....	312	Bacterial peptide deformylase inhibitors	1607
covalent regulation of.....	315	as antibacterial agents	1607
drug-metabolizing enzymes.....	311	bacterial resistance to	1618
expression of.....	312	class I	1613
genetic polymorphisms of.....	312	class II	1613
regulation of.....	311	class III	1614
regulation of expression of	314	clinical candidates of	1618
structural data of.....	315	discovery of	1611
structure of	311	with <i>in vivo</i> activities	1617
Arylpiperazines	1734,1746	Bafilomycin A ₁	1952
with mixed receptors profile	1746	Evans' total synthesis of	1952
Asbestos	2608	Hanessian's total synthesis of	1961
apoptosis by	2608	Marshall's total synthesis of	1965
Asparagine linked oligosaccharides	527	Roush's total synthesis of	1952
synthesis of	527	Toshima's total synthesis of	1952
Aspartic mimetic subunits.....	56	Bafilomycin V ₁	1952
Aspartyl proteases	1266	total synthesis of	1952
Aspirin	2756	Basement membranes	1495
chelation therapy for	2757	in chaga's disease	1498
therapeutic approaches to toxicity of	2757	in goodpasture's syndrome.....	1497
Atherogenesis	1763	in tubulointerstitial nephritis	1499
modulation of nitric oxide (NO) pathway in	1763	macromolecular components of	1495
Atherosclerosis	3000,3120	Basement membrane peptides	1495
animal models of	3000	biomedical applications in	1495
role of selectin	3120	functional considerations in	1495
Autoimmune diseases	1537,1892	in chaga's disease	1498
advances in	1537	in good pasture's syndrome	1497
		in tubulointerstitial nephritis	1499
		BCR aggregation	1900
		models of	1900

Benzimidazole-2-thiones	1023	cross-reactivity to other NRs	1024	docking studies of	1024	medicinal chemistry of	1023	pharmacology of	1024
1H-Benzo[F] indazoles	1031	cross-reactivity to other NRs	1031	medicinal chemistry of	1031	pharmacology of	1031		
Benzodiazepines	2608								
Benzo-fused seven-membered 5-FU <i>O,N</i> -acetals	1427								
Benzoisoxazoles (LXR)	1070	medicinal chemistry of	1070	pharmacology of	1070				
Benzopyrano [3,4-F] quinolines	1036	cross-reactivity to other NRs	1037	medicinal chemistry of	1036	pharmacology of	1037		
Benzoxanthenes	2460								
(3 <i>H</i>)-Benzoxazolone	877	chemical reactivity of	877	in design of pharmacological probes	877,880	therapeutic applications of	877,882		
1-Benzyl-3-sulfanylphenyl indoles	1056	cross-reactivity to other NRs	1056	medicinal chemistry	1056	pharmacology of	1056		
Benzyl-EDTA/DOTA Janus bivalent haptens	329	and radioimmunodetection	332	with indium-111-labeled bivalent haptens.....	332				
Betulinic acid	657	analgesic/anti-inflammatory activity of	663	anthelmintic activity of	664	antibacterial activity of	663	anticancer activity of	662
		anti-HIV mechanism of action of	657,661	antimalarial activity of	663	biological properties of	657	derivatives of	657
		metabolic transformation of	664	miscellaneous properties of	664	pharmacokinetics of	665	phytochemical aspects of	657
		structure-activity relationship studies of	658	tissue distribution of	665				
Betulinic acid derivatives	657	analgesic/anti-inflammatory activity of	663	anthelmintic activity of	664	antibacterial activity of	663	anticancer activity of	662
		anti-HIV mechanism of action of	657,661	antimalarial activity of	663	miscellaneous properties of	664	structure-activity relationship studies of	658
Bicyclic androgen receptor modulators	1046	cross-reactivity to other NRs	1048	medicinal chemistry of	1046	pharmacology of	1048		
Bicyclo [2.2.2] octanes	1027	cross-reactivity to other NRs	1029	medicinal chemistry of	1027	pharmacology of	1029		
Bioactive peptides	1905	antimicrobial activity of	1910	antithrombotic activity of	1910	biochemical properties of	1905	biological activities of	1905
		cytomodulatory activity of	1912	encrypted in bovine milk proteins	1905	functional significance of	1912	immunomodulatory effects of	1911
		inhibition of angiotensin-converting-enzyme (ACE) by	1907	mineral binding properties of	1910	opioid agonistic/antagonistic activities of	1905	peripheral target sites of	1914
		structure-activity relationship of	1905	target sites of	1912				
Biodegradable enhancers	2288								
Bioisosterism.....	23	alterations of physicochemical properties by.....	25	as strategy for molecular modification	23,25	classic type	27	classic/non-classic type	25
		classification of.....	25	cyclic vs. non-cyclic	34	for drug design.....	23	non-classic	34
		of mono/di/tri/tetravalent atoms/groups.....	27						
Biological warfare	667	history of	667						
Biological weapons	668	pathogens/toxins as	668						
Biomedical cyclotrons	807	positron-emitting isotopes produced on	807						
Bio-responsive contrast agents	763								
Bis-bananin II-bananin	2137	synthesis of	2137						
Bis-xanthenes	2441								
Bivalent haptens	328	affinity in enhancement system	328	cooperativity of dual binding of	328				
Bladder disorder.....	247	management of.....	247						
Blood pool contrast agents	2802								
Botulinum neurotoxins	247,667,669	as biological warfare agents	669	development of potential inhibitors of	673	in anterior rectocele.....	260	in benign prostatic hyperplasia (BPH).....	255
		in chronic anal fissure.....	260	in chronic idiopathic anal pain	262				

in chronic prostatic pain.....	254	structure of.....	226
in detrusor-sphincter dyssynergia.....	252	targeting	217
in hemorrhoids.....	263	C5A inhibitors.....	231
in hirschsprung's disease	263	with undisclosed action mechanism.....	231
in idiopathic detrusor overactivity	254	Cadmium	1187,2607,2774
in neurogenic detrusor overactivity	254	and aspirin	1188
in other anorectal condition	260	and vitamins C/E	1188
in pain after hemorrhoidectomy.....	263	effect on genes/proteins	1187
in sensor urge.....	254	in apoptosis	1188
in urinary retention	254	in dysfunction of isolated mitochondria	2607
mechanism of action of	670	in DNA repair mechanism	1188
medicinal chemistry of	667	Caffeic acid derivatives	237
pelvic floor indications of.....	257	biological activities of.....	237
prostatic indications of.....	254	biosynthesis of.....	240
signs/symptoms of	670	caffeic acid dimers as.....	238
urinary bladder indications of	252	caffeic acid monomers as	237
Brain anandamide receptor	1388	caffeic acid tetramers as.....	238
Breast cancer	297	caffeic acid trimers as.....	238
advanced	303	chemical synthesis of.....	240
age cut-off in.....	297	chemistry of.....	237
and aging	299	from <i>Salvia miltiorrhiza</i>	237
biology of	299	miscellaneous group of.....	239
chemotherapy of	297	natural resources of.....	239
combination regimens used in	305	structural classification of.....	237
comorbidities of	298	Cancer	1589,2719,3091
early stage of.....	301	as target for therapeutic designs	1589
frailty of.....	298	cell cycle of	1589,2719
in elderly.....	297	cyclin dependent kinase inhibitors (CKIs)	
locally advanced	303	in	1590,1591
new directions for.....	306	cyclin in	1590
oral drugs in.....	306	p27kip1 functional regulation in	1589
single-agent chemotherapy in.....	303	telomerase inhibition in	3091
targeted therapies for.....	306	Cancer immunotherapy.....	629
treatment related toxicity in.....	299	effect of epitope modification	635
Butenolides	3108	vaccine strategies for	630
as inhibitors of QS	3108	Cannabimimetic indenes	1395
C5A 217		medicinal chemistry of	1395
arginine-cage motif of.....	227	pharmacology methods to study	1396
aromatic micro-domain of.....	229	recent developments in	1395
dimerization interface of.....	229	Cannabimimetic indoles	1395
first site antagonists of.....	229	medicinal chemistry of	1395
first site interaction of.....	224	pharmacology methods to study	1396
function of.....	226	recent developments in	1395
in drug dilcovery.....	217	structures of	1400
inhibitors of.....	229	Cannabimimetic pyrrole	1395
interactions with C5 A receptor	223	medicinal chemistry of	1395
natural inhibitors of.....	229	pharmacology methods to study	1396
recent advances in.....	217	recent developments in	1395
role in antiphospholipid syndrome.....	220	Cannabinoid CB ₂ receptor	1217
role in autoimmune diseases	218	modeling of	1221
role in bullous pemphigoid.....	220	targeting of	1217
role in inflammatory lung diseases.....	223	Cannabinoid receptors	1361
role in ischemia/reperfusion injury.....	222	antagonists of	1361
role in psoriasis.....	218	inverse agonists of	1361
role in rheumatoid arthritis	218	Cannabinoid-vanilloid brain receptor	1388
role in sepsis.....	221	Canonical peptide-MHC class 1 interactions	633
second site antagonists of.....	230		
second site interaction of.....	225		

Carbocyclic C-nucleoside analog	2122	development of	1217
synthesis of	2122	modeling of	1217,1221
Carbodithioates	2788	mutations of	1217
Carbonyl cyanide <i>m</i> -chlorophenyl hydrazone (CCCP)	2611	mutation studies of	1218
Carbonylamino-benzimidazoles	1052	CCR5 co-receptor function	1563
cross-reactivity to other NRs	1053	determinants of	1563
medicinal chemistry of	1052	Cell cycle progression	2719
pharmacology of	1053	role of Fe	2719
Carboxylate-based isosteres	3134	Cell membrane	1842
di-anionic	3135	delivery across	1842
mono-anionic	3134	Cellular adhesion molecules (CAM).....	51
Cardiovascular drugs	1755,3119	Cellular penetration.....	81
and platelet adhesion	3119	Central nervous system (CNS)	1513
cholesterol transport inhibitors as	1760	animal models of	1513
exerting antiatherosclerotic activities	1755	bioactive peptides in	1513
fibrates as	1767	mediated diseases	1513
inhibition of acyl coenzyme A as	1762	mimetics in	1513
inhibitors of intestinal epithelial uptake of bile acids as	1762	therapeutic interventions of	1513
PPAR ligands as	1767	Central scaffolds.....	58
statins as	1757	Chaga's disease	945
Carnosine	2293	chemotherapeutics for	945
aldehyde scavenging by	2295	effect of DNA interactions	949
anti-crosslinking properties of	2300	glycolysis pathways in	947
degradation of	2294	identification of	945
derivatives of	2301	pathogenesis of	945
role of carnosinase	2294	prevention of	945
Carnosine-related antioxidants	2293	recent developments in	945
Caspase-1	2963	role of cruzain	949
inhibitors of	2969	role of dihydrofolate reductase	949
Catalytic inhibitors	1288	role of farnesylpyrophosphate synthase	956
Catecholamines	2609	role of geranylgeranylpyrophosphate synthase	956
Caffeic acid monomers	237	role of hypoxanthine phosphoribosyltransferase ..	949
CB ₁ cannabinoid receptor antagonists	1363	role of lanosterol synthase(oxidosqualenecyclase)	957
from aminoalkylindole derivatives	1363	role of peptidases	948
from aryl-imidazolidine-2,4-diones derivatives .	1374	role of squalene synthase	956
from azetidine derivatives	1374	role of <i>Trypanosoma cruzi</i>	945
from cannabidiol derivatives	1363	role of trypanothione reductase	953
from diarylimidazoles derivatives	1375	treatment of	945
from 3,4-diaryl-pyrazoline derivatives	1377	undetermined targets of	947
from diaryl-pyrazine/diphenyl-pyridine diphenyl -phenyl/diaryl-pyrimidines derivatives	1378	Chalcones	483
from diarylpyrazole derivatives	1364	and inhibition of nitric oxide	496
from phenyl benzofuranone derivatives	1373	anti-invasive	496
from tetrahydrocannabinol	1363	antioxidant property of	492
inverse agonists of	1363	chemoprotective property of	483,493
CB ₂ ligands receptor antagonists	1382	cytotoxic property of	483,487
from classical cannabinoid derivatives	1382	inhibition/induction of metabolizing enzymes for	495
from diarylpyrazole derivatives	1385	physicochemical properties of	485
from indole derivatives	1382	recent developments in synthesis of	483
from other pyrazole derivatives	1385	Chelating agents	2765
from 2-oxoquinoline derivatives	1385	for plutonium/uranium removal in radiation emergency medicine	2765
inverse agonists of	1382	use of	2765
CB ₂ selective ligands	1217	Chelating drugs	2668,2697
bioassay methods for	1223	mode of action of	2697
		historic perspective in selection development	
		use of	2669

Chelators	2731,2771	Combinatorial biosynthesis	1669
as antidotes	2771	implications for	1669
effects of	2731	Combinatorial natural products	703
in clinical use	2779	analysis of	707
in metal toxicity	2771	analytical approaches towards	704
therapeutic/experimental aspects of	2771	automated/manual extraction methods in	704
Chemiosmosis	2604	blast search/cloning in	703
ATP generation by	2604	cloning to analysis of	703
Chemokine receptors	1245	optimization of separation systems in	706
Chemotherapeutic agents	567	Complex xanthenes	2458
Chiral enhancers	2288	synthesis of	2458
Chiral PNAs	2574	Concanamycin F	1973
Chloramphenicol	2609	Paterson' total synthesis of	1977
Chlorinated xanthenes	2514	Toshima's total synthesis of	1973
Chondrodysplasias	388	total syntheses of	1973
SLC26A2 mutations in	388	Conformationally restricted peptides	471
Chromatography	501,1339	amide bond formation to	472,473
in analysis of serum	521	amine bridge formation to	473
in diagnosis purpose	521	as tools	471
in QSRR based on molecular properties	502	carbonyl bridge formation to	476
measurement of binding affinity using liquid	511	disulfide bond formation to	475
of guanidino compounds	520	in opioid receptor studies	471
of metabolites of aromatic amino acids	517	monosulfide bridge formation to	476
role in molecular interaction	502	role of cyclic amino acids	476
Chromium	1177	Congenital chloride diarrhea	389
activation of transcription factors by	1178	SLC26A3 mutations in	389
as biological reductants	1178	Congestive heart failure (CHF)	1439
Chronic fatigue syndrome	1805	B-type natriuretic peptide in	1439
experimental data of	1806	chronic subcutaneous dosing in	1445
therapy of	1807	classification of	1439
<i>cis/-trans-1-[3-(hydroxymethyl)-1,4-dioxepan-5-yl]</i>		oral BNP in	1445
pyrimidines	1423	pharmacological agents for	1439
antiviral activities of	1425	role of BNP in treatment of	1443
in anticancer therapy	1425	serial infusions of BNP in	1445
in breast cancer	1426	subcutaneous administration of AlbuBNP in	1445
Cisplatin	2078	therapeutic approaches in treatment of	1440
mode of action of	2078	use of ACE inhibitors	1440
structure-activity relationships of	2078	use of aldosterone receptor antagonists	1441
Classical cannabinoids	1223	use of angiotensin receptor blockers (ARBs)	1441
Cloning	704	use of beta blockers	1441
by transfection	704	use of calcium channel blockers	1441
Coagulation cascade	397	use of digitalis	1442
anticoagulants in	400	use of diuretics	1442
antiplatelets in	399	use of inotropic agents	1442
endogenous inhibitors of	397	use of natreacor	1444
modulators of	397	use of vasodilators/nitrates	1442
towards cell-based model	397	Contrast agents	2795
Cobalt	1180	classification of	2797
Combinatorial-based approach	17	<i>Mangafodipir trisodium</i> as	2799
natural product by	17	mechanism of action of	2795
Combinatorial biocatalysis	1669	Copper	811,1172,2163,2607,2753,2777
implications for	1669	active transport of	2171
		and vitamins E/C/selenium	1176
		antioxidant therapy to	2759
		antiviral activity of	2166
		as acaricide	2165
		as algicide	2165
		as bactericide	2163
		as biocidal tool	2163

as fungicide	2165	as anti-inflammatory	910
as molluscicide	2165	as antimicrobial	908
as water purifier	2164	as antioxidant	910
chelation therapy of	2753	as antiviral	908
effect of decrease in metal sensitivity of		as molluscicidal	908
cellular targets	2172	biological activity of	887, 907
effect of enzymatic detoxification of metal		cardiovascular effects of	910
to form	2172	central nervous system (CNS) effects of	910
effect of extracellular sequestration	2172	enzyme inhibition by	909
effect of intracellular sequestration of metals		identification of	898
by protein binding	2171	in medicinal chemistry	887
effect of metal exclusion by permeability		methods of synthesis of	898
barrier	2170	natural occurrence of	888
and free radicals	1174	occurrence of	887
further uses of	812	other applications of	910
in homeostasis	1172	prodrug strategy of	910
in neurodegenerative disorders	1175	separation of	898
induced toxicity	1176	synthesis of	887
interaction with nucleic acids	2168	CPT-11-induced diarrhea	1350
labeled antibodies of	811	anticholinergic agents for	1350
mechanisms of antiviral/antifungal/anti-algae		role of cytokines/cytokine inducers	1352
activities of	2169	role of enzyme inducers	1350
mechanisms of toxicity in microorganisms by	2167	role of inhibitors of carboxylesterases	1350
mediated cell membrane damage	2167	use of COX-2 inhibitors	1353
mediated protein damage	2169	use of cytokine inhibitors	1352
metabolism of	2756	use of glutamine	1350
metallothionine up-regulation of	2758	use of inhibitors of drug transporter	1351
microbial resistance to	2170	use of loperamide	1350
peptides of	811	use of octreotide	1350
proteins of	811	use of oral alkalinizing agents	1352
therapeutic approaches to	2758	use of oral antibiotics	1351
toxicity of	2607,2756	CRF receptors	1505
toxicology of	2753	CRF receptor types I (CRF1)	1505
Copper Bis-thiosemicarbazones	811	CRF2	1505
Copper ligands	810	family of	1505
design of	810	CRF-binding protein (CRFBP)	1505
Corticotropin-releasing factor (CRF)	1503	Crystal violet	2608
and hypothalamus-pituitary-adrenal (HPA)		CXCR4 co-receptor function	1556
axis	1503	determinants of	1565
and macrophages	1506	2-Cyano-1,2,3,6- tetrahydropyridines	556
calcium ion trafficking of	1505	synthetic applications of	556
effects at site of inflammation	1505	Cyclamine tricyclic xanthone derivatives	2544
family of neuropeptides	1503	preparation of	2544
in female reproductive tract	1507	Cyclic/acyclic amidines	1022
in inflammation	1503,1505	cross-reactivity to other NRs	1022
in inflammatory phenomena associated to	1507	medicinal chemistry of	1022
differentiation of endometrial stroma to		Cyclic depsipeptides	862
decidua	1507	synthesis of	862
in mast cells	1506	Cyclins	2720
in gastrointestinal tract	1509	Cyclin-dependent kinase	1252,2720
maternal immune tolerance by	1508	catalytic dimers of	2720
peptides in adrenals	1504	Cyclin-dependent kinase inhibitors (CDKI)	2720
peptides in heart	1504	1,2-Cyclohexyl PNAs	2580
peptides in placenta	1505	1,2-Cyclopentyl PNAs	2582
PKC signaling pathways of	1505	Cys-based protein tyrosine phosphatases	1859
role of protein kinase A (PKA)	1505	effect of nitrogen species	1859
signaling of	1505	effect of reactive oxygen	1859
therapeutic applications of	1503		
Coumarins analogues	887		
as anticancer	908		
as anticoagulant	910		

in basophils	1859	pharmacological modulation of	1924
in mast cells	1859	pharmacologically induced regulatory	1923
regulation of class I/II	1866	phenotypic plasticity of	1786
regulation of	1859	presentation of lipid antigens of	1790
Cysteine proteases	1266	role in generation of regulatory immuno/ suppressive effectors	1921
Cytokine inhibiting antedugs	2236	role of Fc receptors (FcR)	1790
for asthma treatment	2236	role of TNF family receptors	1791
		role of toll-like receptors (TLRs)	1790
		targets in immunomodulation of	1922
		therapeutic effects of	1794
DDP IV inhibitors	991	2-Deoxy-2-[¹⁸ F]fluoro-D-glucose (FDG)	790
for treatment of type 2 diabetes	991	measurement of glucose metabolism using FDG	790
Defecation disorders.....	258	3'-Deoxy-3'-[¹⁸ F]fluorothymidine (FLT)	791
physiopathology of.....	258	assessment of proliferation using	791
Deferiprone	2663,2784	Diabetes mellitus	1940
combination therapy using	2673	drugs used to/treat	1940
use of	2663	(±)-Diazon analog azodiazon	2128
Deferoxamine	2663,2783	synthesis of	2128
combination therapy using	2673	Diazonofol	2131
use of	2663	synthesis of	2131
Dendritic cells	1783,1921	Diclofenac	2610
activation kinetics of	1794	Differential scanning calorimetry	2011
activation of	1783	and protein folding/stability	2013
and prostaglandin	1924	application in drug design	2011
and steroids	1924	in drug-lipid interaction	2016
and tryptophan metabolites	1924	in drug/protein-DNA interaction	2018
and vitamin D (VIT D3)	1925	in life science	2011
antigen/peptide approach for	1793	in molecular recognition	2011,2014
antigen presentation of	1789	in protein-ligand interaction	2014
applications for cancer immunotherapy	1783	in protein-protein/lipid	2016
as pharmacological targets	1921	in stability	2011
based cancer immunotherapy	1792	in thermodynamics	2011
based clinical trials	1795	Digitalis inotropic agents	2345
classical pathways of	1789	Digitalis-like compounds	2343
cross-presentation of	1789	acyclic chains of	2346
effect of aspirin	1926	-butylolactone at	2346
effect of calcineurin inhibitors	1925	effect on Na ⁺ ,K ⁺ -ATPase	2343
effect of cyclosporin A (CsA)	1926	replacement of unsaturated	2346
effect of flavonoids	1927	Dihydroindol-2-ones	1058
effect of mycophenolate mofetil (MMF)	1926	medicinal chemistry of	1058
effect of rapamycin	1927	1,4-Dihydropyridine derivatives	2609
effect of statins	1926	Dihydroquinolines/benzopyrano [3,4-F] quinolines/ (2-oxo-2-thiono) benzoxazines (2-oxo/2-thiono)	
effect of tacrolimus (FK506)	1926	indoles	1025
<i>ex vivo</i> for cancer immunotherapy	1787	cross-reactivity to other NRs	1026
functionality of	1787	medicinal chemistry of	1025
generation for cancer immunotherapy	1787	pharmacology of	1026
heterogeneity of	1784	2-position switch of	1026
human type	1785	6-position switch of	1026
immunobiology of	1788	Dimercaprol (BAL)	2779
in allo-recognition	1923	Dimerization inhibitors	1286
in genetic modification	1794	Dioxin (TCDD)	2611
in homeostasis	1922		
in tumor cell lysate/fusion	1793		
<i>in vitro</i> differentiation of	1787		
lineage of	1784		
maturation of	1783,1787,1922		
microarray technology for studies on	1791		
migration of	1791,1922		
murine development of	1785		
murine subsets of	1785		
naturally occurring regulatory	1922		

Dipeptidyl peptidase IV (DPP IV)	971	arylaminoalcohols as	134
active site at	974	as cytotoxic agents.....	127
catalytic mechanism of	980	coumarins as.....	137
classification of	971	miscellaneous types of.....	146
competitive inhibitors of	981	molecules as.....	130
distribution of	980	phenanthridines as.....	140
effect on chemokines	990	quinolines as.....	143
effect on other neuropeptides	987	quinoxalines as.....	143
effect on PACAP/glucagon family of peptides ..	988	resistance of.....	129
effect on pancreatic polypeptide family	987	selectivity of.....	129
functions in proteolysis of bioactive peptides ..	987	DNA-ligands	2805
functions in immune system/HIV-1 entry	990	biology of	2805
inhibitors of	971,981	chemistry of	2805
interaction sites of	978	DNA-binding of	2805
irreversible inhibitors of	986	with groove binding	2805
non-peptidic reversible inhibitors of	985	with intercalating/alkylating activity	2805
peptide-derived reversible inhibitors of	981	DNA-targeted platinum complexes	2184
physiological functions of	987	DNP bivalent haptens	329
role in cancer progression/cell adhesion	991	Dopamine autoreceptor agonist	560
role in intestinal/renal handling of proline		Drug delivery systems	1841
containing peptides	987	adeno-associated viruses (AAV) based	1843
role in psychoneuroendocrine functions	990	adenoviruses based	1843
slow/tight-binding inhibitors of	983	alphavirus based	1844
structure of	974	bacterial-mediated	1848
substrate specificity of	978	baculovirus based	1844
therapeutic perspectives of	971,993	bioavailability in	1851
Dipyridyl thiosemicarbazone (DpT) iron chelators	2718	bioshuttle-mediated	1850
Disintegrins	1457	by transcytosis of nanoparticles	1849
small peptides of	1457	by transfection	1848
Dispiro compound AZOCYS	2119	characterization of	1841
synthesis of	2119	charge dependant-mechanical	1846
Distamycin A	2805	development of	1841
analogues of	2805	EGF-receptor endocytosis for	1845
2,6-Disubstituted THP's	557	first-pass-effect in	1852
<i>cis-trans</i> isomerization of	557	for mammalian cells/tissues	1841
DMXAA	2528	formulations for optimizing resorption	1852
as antivasular agent	2528	future considerations of	1854
DNA alkylating agent	2903	galenical modifications of	1851
DNA cross-linking	2903	human insulin receptor (HIR) based	1846
DNA microarray methodology	1149	hydrogel mediated	1853
data analysis in	1149	immunoliposomes mediated	1847
DNA polymerases	645	lentiviruses based	1844
efficiency of photoaffinity	645	local application of	1852
DNA repair	641	long-circulating liposomes mediated	1846
photoaffinity labeling technique for	641	microneedles in	1852
study of	641	non-viral delivery strategies	1845
DNA replication	641	octreotide mediated	1845
photoaffinity labeling technique for	641	oral application of	1851
study of	641	orally applied drug delivery as	1852
DNA template	645	other viral delivery systems as	1845
efficiency of photoaffinity	645	peptides for	1850
DNA-intercalators	127	protoplast fusions based	1848
acridines as.....	130	pulmonary delivery in	1854
alkaloids as.....	132	receptor-independent (nucleic acid transfections)	
anthracenediones as	134	based	1846
anthracyclines as.....	133	rectal delivery in	1854
		resorption in	1851
		retroviruses based	1843
		role of polybrene/DMSO	1848
		role of albumin	1849

role of Ca-phosphate	1847	dUMP analogues	2248
role of carbohydrates polymers- (chitosan/dextran)	1849	Ecdysteroids.....	153
role of cationic polymers polyethylenimine (PEI)	1847	antioxidant effect of.....	165
role of dendrimers	1847	as antiarrhythmic	165
role of diethylaminomethyl-dextran (deae-dextran)	1847	carbohydrate metabolism stimulation by.....	163
role of electroporation	1848	chemical structure of.....	158
role of gene gun	1847	difficulties in isolation of.....	162
role of glucose	1849	effects on lipid biosynthesis	164
role of macromolecules	1848	effects on renal dysfunction.....	164
role of nanoparticles	1849	effects on urea balance	164
role of photochemical transfection	1848	extraction/prepurification of.....	159
role of poly <i>N</i> -(2-hydroxypropyl) methacrylamide	1849	gene regulation system.....	167
role of polyethyleneglycol	1849	hepatoprotection by.....	164
role of silicones	1849	immunostimulant effect of.....	165
role of ultrasound (sonophoresis)	1848	in treatments of humans	166
stealth-liposomes mediated	1847	inducible mammalian expression system.....	168
surface-modified liposomes mediated	1846	isolation of.....	153
systemic application of	1852	low toxicity of.....	165
target-directed	1852	model system for PCD.....	170
thermo-sensitive liposomes mediated	1847	molecular mechanisms of action of.....	167
tissue directed	1853	on-line spectroscopic analysis of.....	162
topical drug delivery	1853	other effects of.....	165
transdermal transport of active agents <i>via</i>	1852	pharmacological effects of.....	163
transferrin mediated uptake for	1845	physiological effects of	163
transmembrane transport peptides in	1850	production scale isolation of.....	159
tumor addressed	1853	prospects in genomic drug discovery.....	167
Drug discovery	501	purification by low-pressure chromatography.....	159
chromatography for	501	purification by repeated LCHPLC.....	161
computational chemical analysis for	501,514	EGFR inhibitors	1776
developments in other related technologies	522	Ehrlich BN	2109
drug-albumin binding affinity in	510	syntheses of	2109
technological developments in	501	Eicosanoid derivatives	1225
Drug permeation routes	2276	Electrical cardioversion	1335
investigation of	2277	recurrence of atrial fibrillation after	1335
structure of	2277	Electron transfer (ET)	2601
dTDP-activated deoxysugars	1640	and amino compounds	2601
syntheses of	1640	and aromatic nitro	2601
dTDP-activated dideoxy-hexoses	1653	and imines	2602
chemical synthesis of	1653	and iminiums	2602
syntheses of	1653	and metal compounds	2601
dTDP-activated monodeoxy-hexoses	1648	and quinones	2601
chemical synthesis of	1648	and radiation	2606
chemo-enzymatic synthesis of	1650	in oxygen radical formation	2605
syntheses of	1648	role of reactive nitrogen species (NO/PN)	2606
dTDP-activated trideoxy-hexoses	1659	Ellipticines	2608
chemical synthesis of	1659	Endocannabinoid	1413
chemoenzymatic synthesis of	1661	biosynthesis of	1414
syntheses of	1659	degradation of	1414
dTDP-deoxysugars	1663	Endocannabinoid-related enzymes	1413
biocatalytic synthesis of	1663	as drug targets	1413
enzymes in	1663	Endothelial anandamide receptor	1387
DTPA-indium bivalent haptens	329	Endothelium	2358
bispecific antibody valency for	332	basic anatomy of	2358
tumor antigen	332	in control of oxidative state	2360
		in control of permeability to cells	2361
		in control of permeability to molecules	2361

in control of vascular integrity/remodelling	2359	indenes as	1115
in physiology	2358	indeno [1,2-] quinolines as	1126
in pathology	2358	indenones as	1114
in vessel wall	2358	isochromanes as	1108
Enzymes	1276	naphthalenes as	1117
Enzyme-responsive contrast agents	764	2-phenyl-benzofurans as	1123
role in human disease	764	quinolines as	1119
Ergolines	1730	tetracyclic chromanes as	1125
ER agonists	1083	tetrahydroisoquinolines as	1110
benzo[] azepines as	1084	thiophene-1-carbaldehydes as	1125
furans as	1086	ER selective antagonists	1126
imidazoles as	1084	benzo [] fluorenes as	1127
isoxazoles as	1084	triazines as	1127
oxazoles as	1084	Estradiol	2610
pyrazines as	1083	Estrogen biosynthesis	497
pyrazoles as	1084	inhibition of	497
pyridazines as	1083	Estrogen receptor	1077
pyrimidines as	1083	biology of	1078
pyrroles as	1086	structure of	1080
thiazoles as	1084	subtype selective ER ligands of	1083
thiophenes as	1086	EthylVANBA	2109
ER /ER	1080	syntheses of	2109
interaction with ligands	1082	Eugenolbananin	2117
structure of	1080	synthesis of	2117
ER agonist/ER antagonist	1129	Eugenolvanillinbananin	2117
dual-profile estrogens as	1129	synthesis of	2117
1,1-diarylethylenes as	1131	Experimental autoimmune encephalomyelitis (EAE)	2947
pyrazines as	1131	anti-CD3 MAb in	2952
tetrahydrochrysenes as	1129	anti-CD4 MAb in	2952
therapeutic prospects of subtypeselective		anti-CD11 MAb in	2953
ligands of	1131	anti-CD40 MAb in	2953
ER antagonists	1087	anti-CD52 MAb in	2953
benzanthracenes as	1105	anti-IL-12 MAb in	2954
benzopyrans as	1099	anti-inflammatory immunotherapies in	2947,2952
benzothiophenes as	1087	anti-TNF MAb in	2955
benzoxathiins as	1091	anti- 4 1 integrin MAb in	2954
1,1-diarylalkylidenes as	1104	anti- 7 integrin MABs in	2954
flavanones as	1091	Ca ²⁺ homeostasis in	2949
furans as	1104	combinational approaches to block	
phenantrenes as	1105	inflammation in	2956
2-phenyl substituents	1087	cytokine-based immunointervention by	
pyrazoles/isoxazoles as	1103	anti-cytokine mAbs in	2954
tetracyclic benzothiophenes as	1105	design/effect of MBP cyclic analogues in	1517
tetrahydroisoquinolines as	1100	differences/similarities of	2948
tetrahydroquinolines as	1102	disruption of costimulation by MAb aganist	
ER selective agonists	1106	B7-1/B7-2 in	2954
benxoxazoles as	1122	excitotoxicity in	2949
benzimidazoles as	1111	induction of regulatory cells in	2955
benzisoxazoles as	1120	MAb against adhesion molecules in	2953
benzo[b]fluorenes as	1126	MAb against chemokines in therapy for	2953
benzothiazoles as	1122	MAb therapy directed against autoreactive	
benzothiophenes as	1113	T-cells in	2952
benzoxazines as	1111	neuroprotection in	2957
bicyclo-[3.3.1]-nonenes as	1113	targeting intracellular signaling pathways in	2955
biphenyls as	1115	Extracellular contrast agents	2797
chromanes as	1109	¹⁹ F NMR	828
constrained phytoestrogens as	1107	effect on blood	840
diarylpropionitriles as	1111		
flavonoids as	1106		

in detection of calcium ions	832	Fluoropyrimidine drugs	841
in detection of magnesium ions	833	Foldamer SOCN-1 carrier	1474
in other biological relevant ligands	833	applications in vaccine development for human use	1477
of fluorinated vitamin B6 derivatives	828	biological studies of	1475
of fluoro amino acids	828	conformational analysis of	1474
of fluorophenols	829	myeloptides in	1477
of metal ions	830	Formamicin	1981
of other <i>pH</i> reporters	829	total synthesis of	1981
Factor VIIa	397	Frataxin	2715
antagonists of	406	Free radicals	1164, 2601
complex of	397	Fructoinosine	2134
exosite inhibitors of	406	synthesis of	2134
focus of	397	Fructovir	2134
in angiogenesis	401	synthesis of	2134
in cancer	401	5-FU 1430	
inhibitors of	397	against molecular markers	1434
peptidomimetics of	408	and apoptosis markers	1435
recent advances in	397	anticancer activities in human breast cancer	
small molecular weight inhibitors of	408	MCF-7 cell cell cycle distribution of	1434
synthetic peptides as modulators of activity of	406	line of	1434
Fanconi anemia	2733	modification of molecular markers by	1435
antioxidants in	2733	toxicity of	1436
chelators in	2733	Furanoxanthones	2458
treatment of	2733	FXR/LXR modulators	1058
Ferritin	2715	G protein-coupled receptors (GPCRs)	3027
Ferrokinetics	2666	G1-S transition	1591
in idiopathic haemochromatosis	2666	role of p27	1591
in transfusional iron overload	2666	GABA uptake inhibitors	562
Flavin derivatives	2608	as anticonvulsants	562
Flavonoids	2610	as sedatives	562
¹⁹ Flourine	819	Gadolinium	751
and magnetic resonance	819	in medicinal chemistry	751
as <i>in vivo</i> NMR probe	820	Gallium-66	812
as reporter	819	gallium as	812
drug uptake of	840	Gallium chelates	812
in non-invasive physiology	819	citrate/transferrin of	812
in pharmacology	819	design of	812
metabolism of	840	labeling of biomolecules	812
Fluorescence imaging	795	GASP	2053
brightness of	796	molecular modeling using	2053
chemical stability of	797	Gastric mucosal defence.....	208
green fluorescent protein in	801	centrally-induced.....	208
in photodegradation	797	Gastric mucosal protection.....	203
<i>in vivo</i>	795	additional receptors mediated	207
of tumors	795	gene-therapy in.....	203
organic fluorochromes in	796	mediators in.....	204
phototoxicity of	799	receptors in.....	204
quantum dots in	799	role of α -adrenoceptors.....	207
role of luciferases	802	role of β -adrenoceptors.....	207
role of optical probes	801	role of adrenergic receptors	207
targeting tumors by	802	role of cannabinoid receptors.....	207
Fluorescence intensity distribution analysis (FIDA) ...	2551	role of histamine receptors.....	207
application to ligand-GPCR binding assays	2555		
based HTS	2557		
Fluorinated PNAs	2576		
Fluorodeoxyglucose	841		
metabolism of	841		

role of nitric oxide.....	205	Glycosyltransferases	1665
role of opioid receptors.....	208	capabilities of	1665
role of prostaglandins	203	combinatorial techniques for	1665
role of sensory neuropeptides	206	promiscuity of	1665
Gastric ulcer healing.....	209	Gossypol	2610
role of exogenously applied growth factors	209	Gp120	1552
role of growth factors.....	209	cell receptor association of	1552
role of vasoactive substances	209	Gp120 V3 peptide	1552
Gene expression	83, 779	in CCR5 mediated deregulation of T lymphocyte function	1552
measurement of	784	G-protein coupled receptors (GPCR).....	961, 1239, 2551
recruitment of cellular enzymes for.....	83	accessory molecules of	967
scintigraphic imaging of	779	associated regulators of G protein	967
sequence-specific regulation of	83	based upon structurally privileged cores	1251
therapy monitoring in	789	characterizing of multiple subtypes of	967
using <i>in vivo</i> reporter genes for	784	confocal fluorescence microscopy for	2551
visualization of vector distribution in	786	design of	1245
Gene expression profiles	1149	directed HTS	2556
adding semantics to	1149	engineering G protein for functional assessment in yeast	964
classification of cell types in	1151	expression in protease-deficient yeast strains	964
cluster analysis in	1151	expression of chimeric	963
extraction of regulatory motifs of	1150	focused libraries	1251
inference of functional annotation in	1151	for biochemical ligand-receptor binding assay	2553
role of self-organizing maps	1152	functional expression in <i>S. cerevisiae</i>	963
tools for drug discovery	1149	high-throughput screening of	2551
using clustering algorithms	1151	influence of yeast culture on functional expression of	964
using hierarchical clustering	1151	mutagenesis studies of	967
using <i>k</i> -means clustering	1152	pharmacological assessment of	961
using mixed clustering	1155	post-translational modifications in yeast	964
using semantic clustering	1152	role of confocal fluorescence fluctuation spectroscopy	2554
Gene reporters	823	role of reporters	964
Gene transfer	779	screening tool for	961
measurement of	784	SPA/-FP-/FIDA approach to	2556
scintigraphic imaging of	779	synthesis of targeted compound libraries	1245
therapy monitoring in	789	yeast modifications to increase biosensor sensitivity for	965
using <i>in vivo</i> reporter genes for	784	yeast system for	961
visualization during gene therapy with suicide genes	786	GPCR ligands	1248
visualization of vector distribution in	786	from biogenic amines	1248
Generic protease-focused libraries	1275	from eicosanoids	1249
GI Imaging	840	from excitatory amino acid/ions	1248
Glucocorticoids	2228	from lipids	1249
as model drugs for antedrug design	2228	from nucleosides	1249
Glucocorticoid receptor modulators	1027	from purines	1249
bicyclo [2.2.2] octanes as	1027	Gram-negative bacteria	3103
1H-benzo [] indazoles as	1032	targeting chemical communication in	3103
Glutamate	2041	GT56-252	2663
uptake into synaptic vesicles	2041	as experimental chelators	2663
Glutamate excitotoxicity	2949	use of	2663
CNS glial cells in	2949	Guanidino compounds	520
Glutamate vesicular transporter (VGLUT)	2041	analysis of	520
inhibitors of	2041	Halogen radiolabeling	813
miscellaneous inhibitors of	2050	chemistry for	813
pharmacophore for	2052,2053		
Glycosidic xanthenes	2513		
Glycosylated xanthenes	2422		

Halogenated xanthenes	2545	Highly active antiretroviral therapy (HAAER)	1705
evaluation of	2545	clinical trials of	1712
HCV infections	2317	effect of cells of macrophage lineage	1708
boronate based inhibitors in	2320	effect of peripheral blood monocytes	1708
C-termini <i>N</i> -acyl sulfonamide based inhibitors		effect of resting memory CD4 ⁺ RO ⁺ T cells ...	1708
in	2338	effect of tissue macrophages	1709
-ketoamide based inhibitors	2328	failure to eradicate HIV by	1712
-ketoacid based inhibitors in	2322	mechanisms failure of	1705
peptidyl acid based inhibitors in	2325	effect of viral compartmentalization/tissue	
peptidyl aldehyde based inhibitors in	2319	reservoirs	1709
pyrrolidine-5,5- <i>trans</i> -lactam based inhibitors ...	2326	to eradicate HIV-1	1705
HCV NS3-4A protease	2317	Histamine-succinyl-glycine bivalent haptens.....	329
as anti-HCV drug target	2318	cytokine pretargeting	334
small-molecule inhibitors of	2317	Iodine-131-labeled bivalent haptens	333
<i>Helicobacter pylori</i>	375	RAIT with.....	333
<i>Helicobacter pylori</i> infection	375	Histone deacetylase	2867
classical triple therapies for	375	non-hydroxamate inhibitors of	2869
first line treatment of	375	HIV disease	1811
fluoroquinolones against	378,380	antioxidant therapy in	1812
furazolidone against	378,379	role of oxidative stress in	1811
levofloxacin/rifabutin triple therapy of	380	HIV-1	1811
macrolides against	377	targets of replicative cycle of	1811
new first line treatments of	377	HIV-1 entry	1552
other strategies to treat	381	gp120 peptide-co-receptor interaction in	1552
quadruple therapy of	378	HIV-1 gp120/V3 immunogenic domains	1551
rescue treatments of	380	conformational properties of	1551
rifabutin against	380	HLA-DR 1	2857
second line treatments of	379	Hormone-refractory prostate cancer (HRPC).....	277
sequential treatment of	378	definition of.....	277
treatment of	375	epigenetic therapeutics for.....	291
Heme	2542,2744	future perspectives for.....	292
cross-linking of	2744	gene therapy in.....	281
proton NMR studies of interaction with 4,5-		immunotherapy in.....	278
dihydroxyxanthone (45X2)	2542	novel biological agents for	277
to protein cross-linking	2747	novel therapeutic strategies for.....	278
Heme oxygenase	2750	role of androgen receptor (AR).....	278
Heme protein-induced lipid oxidation	2742	treatment of	277
and isoprostane formation	2742	tumour necrosis factor (TNF)-targeted	
Hemoglobin	2741	therapeutics for.....	287
as pro-oxidant enzymes	2741	use of angiostatin.....	289
associated oxidative stress	2741	use of ansamycins	283
based blood substitutes/oxidative stress	2749	use of anti-adhesion agents	290
from molecular mechanisms to disease states ...	2741	use of anti-metastatic agents	289
pro-oxidant/pseudo-peroxidase activities of	2744	use of anti-VEGF	289
redox/radical chemistry of	2741	use of apoptosis regulators.....	283
Hemosiderin	2715	use of calcitriol	290
Heterocyclic hydroxylated -amino acids	3074	use of carboxyamido-triazole (CAT).....	289
Heterocyclic moiety-containing fused benzene deriv-		use of cell-cycle regulators.....	287
atives	1053	use of cyclo-oxygenase (COX)-2 inhibitors	291
cross-reactivity to other NRs	1053	use of differentiation agents	290
medicinal chemistry of	1053	use of endostatin.....	289
pharmacology of	1053	use of endothelin-1 (ET-1) antagonists.....	287
Hexafluoro-2-(phenyl) isopropanols (LXR)	1066, 1072	use of farnesyl-protein transferase (FPTase)	
3D information of	1067	inhibitors.....	282
medicinal chemistry of	1066, 1072	use of growth factor inhibitors	281
pharmacology of	1066, 1072	use of histone deacetylase (HDAC) inhibitors.....	291
		use of hypomethylating agents	291
		use of inhibitors of epidermal growth factor	
		receptor (EGFR).....	281

use of inhibitors of platelet-derived growth factor receptor (PDGFR).....	281	Hydantoins	1051
use of inhibitors of insulin-like growth factor receptor (IGFR).....	281	cross-reactivity to other NRs	1052
use of mammalian target of rapamycin (mTOR) inhibitors.....	282	medicinal chemistry of	1051
use of 2-methoxyestradiol (panzem).....	287	pharmacology of	1052
use of mitogen-activated protein kinase (MAPK) inhibitors.....	282	2-Hydroxy-3-[1-(3-trifluoromethylphenyl) cyclopropyl] propionylamido	1022
use of MMPs inhibitors.....	289	cross-reactivity to other NRs	1023
use of neo-angiogenesis inhibitors.....	288	medicinal chemistry of	1022
use of novel biological agents.....	281	pharmacology of	1023
use of peroxisome proliferator-activated receptors (PPAR)- agonists.....	290	1-(4-Hydroxy-3-methoxyphenyl) 2,8,9-trioxadamantane-3,5,7-triol (VANBA)	2109
use of phenylacetate/analogues	291	base-catalyzed synthesis of	2109
use of proteasome inhibitors	288	4-Hydroxyanisole	2609
use of protein kinase C (PKC) inhibitors.....	283	Hydroxylamine	2608
use of RAF kinase inhibitors	282	Hydroxylated cyclic α -amino acid derivatives	3063
use of retinoids	290	syntheses of	3063
use of signal transduction inhibitors.....	281	Hydroxylated xanthenes	2499
use of SU5416	289	containing bisdihydrofuran ring system	2514
use of SU6668.....	289	containing crown ether	2514
use of suramin	288	crystal packing of	2514
use of survivin inhibitors	287	metal complexes of	2514
use of telomerase inactivators.....	292	Hygrolidin	1969
use of thalidomide/novel analogues	288	total synthesis of	1969
use of TNP-470.....	289	Yonemitsu/Hashimoto's total synthesis of	1969
use of tyrosine kinase inhibitors	282	Hypolipidemic agent	2003
use of zinc/copper.....	291	borane adducts of aliphatic amines as	2003
5HT _{1A} receptor ligands	1721	boron salts as	2005
Human immunodeficiency virus-1 (HIV-1)	1551	boronated nucleosides as	2006
V3 conformational features of	1554	carboxy/cyanoborane adducts of cyclohexylamines/toluidines as	2004
V3 sequence variation of	1553	cholines as	2005
Human immunodeficiency virus type 1 (HIV-1) infection	1705	heterocyclic amine-boranes as	2005
current recommendations for treatment of	1707	metal complexes as	2004
current regimens for	1706	methylimidazole- <i>N</i> -ethylcarbamoylborane as	2006
effect of cells of macrophage lineage	1708	<i>N,N</i> -dimethyloctadecylamine borane as	2004
effect of peripheral blood monocytes	1708	peptides as	2005
effect of resting memory CD4 ⁺ RO ⁺ T cells	1708	4-phenylpiperidine-carbomethoxyborane as	2005
effect of tissue macrophages	1709	phosphine boranes as	2005
effect of viral compartmentalization/tissue reservoirs	1709	tetramethylammonium dodecahydrodecaborate as	2005
immunological barriers in	1709	trimethylamine-carbomethoxyborane as	2003
non-nucleoside reverse transcriptase inhibitors (NNRTIs) in	1706	trimethylamine-carboxyborane as	2003
nucleoside nucleotide reverse transcriptase inhibitors (NRTIs) in	1706	trimethylamine- <i>N</i> -octyl carbamoylborane as	2004
protease inhibitors (PI) in	1707	Hypoxia	838
reverse transcriptase inhibitors in	1706	Hypoxia inducible factor-1	2715
strategies to improve HAART penetration into sanctuary sites in	1714	ICL670	2663
structured treatment interruptions (STI) in	1713	as experimental chelators	2663
targeted killing of infected cells in	1714	use of	2663
Human SLC26 transporters	385	Idiopathic haemochromatosis	2664
pathogenetics of	385	IGF-I R	2882
Hybrid aminocoumarins	422	gene regulation of	2885
by combinatorial biosynthesis	422	in apoptosis	2885
Hybrid receptors	2882	in cancer	2885
		in cell-cycle progression	2885
		pathway in thyroid cancer	2887

pathway in thyroid cells	2886	Insect control	461
signal transduction of	2882	biorational approaches for	461
IGF-I/IGF-I receptor pathway	2881	by enzymatic inhibition `	461
implications in pathophysiology of thyroid		cysteine proteinase inhibitors in	467
cancer	2881	molting hormone mimics	467
IGF-II	2881	phenol oxidase inhibitors in	467
structure of	2881	role of acetylcholinesterase	464
Imaging apoptosis	814	role of aldehyde dehydrogenases	463
applications of ⁸⁶ Y in	815	role of juvenile hormone esterase	465
radiolabeling studies using ⁸⁶ Y	815	role of juvenile hormone epoxide hydrolases	466
radiolabeling studies using ^{94m} Tc	815	role of oxidases	463
Imines	2608	role of pheromone-degrading enzymes	461
Iminiums	2608	role of pheromone esterases	461
3,3'-Iminodipropionitrile (IDPN)	2610	role of proteases	466
Immune response	1532	serine plant inhibitors in	466
modified peptides in	1532	Insulin-like growth factor (IGF)-1	2881
Immunogenicity.....	321	ligand of	2881
Indoles	1227	role in human cancers	2884
Indole-3-acetic acid (IAA)	2611	structure of	2881
Indolylalkylamines	1728	Insulin-like growth factor binding proteins (IGFBPs)	2882
Inflammation	2931,3027	Integrins	1449
anti-inflammatory hormones to treat	2934	dual antagonists of	1449,1457
arylalkanoates to treat	2937	in angiogenesis	1455
benzoic acids to treat	2936	in autoimmune diseases	1456
bradykinin receptors in	3028	in brain disorders	1456
chemokine receptors in	3029	in cancer	1456
complement C3a/C5a receptors	3030	in infectious diseases	1456
copper to treat	2933	in osteoporosis	1455
corticotropin releasing factor receptors	3032	in thromboembolic disorders	1454
cox-1 sparing/cox-2 selective NSAIDs to treat	2939	ligand binding	1452
disease-modifying anti-rheumatic agents to treat	2934	model of activation of	1452
drugs to treat	2931	receptors of	1457
endothelin receptors in	3033	structure of	1450
heterocyclic diones to treat	2933, 2937	tissue distribution of	1453
melanocortin receptors in	3034	Integrin ν_3	1450
neurokinin receptors in	3035	crystal structure of	1450
non-acidic Nsaids to treat	2937	extracellular portion of	1450
non-gastrotoxic (acidic) Nsaids to treat	2938	in complex with RGD ligand	1452
nonpeptide ligands in	3027	Internal radiotherapy	322
other GPCRs in	3038	pharmacokinetics of.....	322
peptide-activated GPCRs in	3027	role of vector format	322
protease activated receptors in	3036	Iodonium salts	2611
salicylates to treat	2933	Ion channels	1275
synthetic glucocorticosteroids to treat	2939	Irinotecan (CPT-11)	1343
therapeutic context of	2932	biochemical mechanisms for induced diarrhea	
Inflammatory arthritis	2943	by	1348
antibody treatments of	2943	clinical factors affecting induced diarrhea by ...	1347
anti-cytokine agents in	2943	conversion of	1345
anti-osteoclast therapies in	2945	drug-associated factors of	1347
B-cell depletion in	2944	early-onset diarrhea by	1348
cell-targeted therapies to	2944	excretion of	1346
inhibition of co-stimulation in	2945	late-onset diarrhea by	1348
T-cell depletion in	2944	metabolism of	1345
Inflammatory disease	2925	patient-associated factors for	1347
inflammatory targets in	2925	pharmacokinetic properties of	1343
therapeutic targets in	2925	plasma pharmacokinetics of	1343
		plasma protein binding of	1346
		transport across biomembrane	1346

Irinotecan-induced diarrhea	1343	medicinal chemistry of	1059
inhibition of	1343	pharmacology of	1061
Iron	1163,2683,2695,2711,2731,2777		
absorption in health/disease	2695	KCNQ potassium channel openers	453
binding of other metals with	2691	acrylamides as	455
binding sites of	2691	benzamides/related compounds as	454
biological function of	2711	developments on	453
catalyzed pathophysiological disorders	2731	2,4-disubstituted pyrimidine-5-carboxamide	
dietary absorption of	2711	derivatives as	455
effect of deprivation on cyclin-dependent kinase		fluoro-oxindole as	455
inhibitors	2721	flupirtine as	454
effect of deprivation on cyclins/cyclin-		in epilepsy	459
dependent kinases	2721	in migraine	459
effect of deprivation on p53/downstream targets	2722	in pain	458
effect of rate of absorption and excretion	2707	<i>N</i> -[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-	
excretion of	2695	acrylamides as	455
excretion pathway in man	2703	retigabine as	454
in homeostasis	1163	therapeutic potential of	458
in regulation of cell cycle control molecules	2721	Kinase-focused libraries	1255
induced carcinogenicity	1166		
induced oxidative stress	1170	Labdanes	1295
mechanisms affecting	2695	abortifacient activity in cattles/sheeps	1310
molecular factors of	2695	anti-algal/phytotoxic activity of	1312
molecular mechanisms of	2711	anti-hypertensive activity of	1310
regulation of absorption of	2713	anti-inflammatory activity of	1310
release of	2691	antimicrobial activity of	1304
role in expression of <i>Ndr</i> g1	2724	anti-PAF activity of	1311
role of natural/synthetic chelators	2695	antiprotozoal activity of	1308
uptake by cells	2711	antituberculosis activity of	1305
Iron chelators	2711,2749	antiviral activity of	1308
and oxidative stress	2749	as -glucuronidase inhibitor	1309
as novel class of antitumor agents	2717	as inhibitors of superoxide anion radical	
treatment of cancer by	2711	release	1309
Iron hexacyanoferrate	2785	as natural sweetening agents	1309
Iron-mediated oxidative damage	1166	as perfumery-spices	1312
targets of	1166	biological activities of	1295,1304
Iron metabolic imbalance	2702	cytotoxic activities of	1305
role of iron excretion in	2702	effect on immune system	1311
Iron overload	2668,2731	endocrine effects of	1312
methods for assessment of	2668	hepatoprotective activity of	1310
Iron overload therapies	2663	insect anti-feedant activity of	1312
advances in	2663	of natural origin	1295
epidemiology of	2664	origin of	1300
iron deposition in	2666	Labdane type diterpenes	1298
toxicity in	2666	activities on enzyme systems	1309
treatment of	2664	as adenylated cyclase enzyme system (AC)	1309
Iron oxide	2795	as -glucuronidase inhibitor	1309
as contrast agents	2795	as inhibitors of adenosine transferase	1309
for magnetic resonance imaging	2795	as inhibitors of aldose reductase	1309
stabilized colloidal particle solutions of	2795	as inhibitors of phospholipase A ₂	1309
Isoxazole inotropic glutamate neurotransmitters	617	as inhibitors of superoxide anion radical release	1309
antagonism of	619	biosynthesis of	1298
ligand binding domain of	618	in fungi	1300
mechanism for agonism of	619	in insects	1300
structure activity relationship (SAR) of	620	in marine organisms	1300
Isoxazole-stilbene carboxylic acids (FXR)	1059	in plants	1300
cross-reactivity to other NRs	1059	role on protein kinases	1309
		Labelled PNAs	2594
		Lactose-PNA conjugates	2591

Lanthanum salts	1631	biological studies of	1475
accumulation in human tissue	1634	conformational analysis of	1474
bioavailability of	1632	mylopeptides in	1477
biological effects of	1635	Magnetic resonance imaging (MRI)	751, 2795
crossing blood-brain barrier	1634	future of	763
gastrointestinal absorption of	1632	mechanism of action of	2795
pharmacokinetics in uremic patients	1632	Magnetic resonance imaging (MRI) contrast agents	751
toxicity of	1635	acyclic chelates as	753
up-take of	1632	biophysics of	751
Lead	2773	blood pool contrast agents as	756
Leeches	3059	dendrimer-based agents as	758
Leishmaniasis	1477	development of	751
surface glycoprotein gp63 of	1477	extracellular agents of	752
Lexitropsins	2805	future developments of	775
analogues of	2805	future of	763
LINAI	2663	historical background of	756
as experimental chelators	2663	liver agents as	753
use of	2663	macrocyclic chelates as	753
Linear peptides	471	vascular agents as	756
cyclization of	471	Major histocompatibility complex (MHC)	1481
Liposomes	1846	peptide presentation by	1481
Liquid chromatography	515	Malaria	2539,2643
analysis of naturally occurring metabolites by	515	alebrin in	2648
Liver fibrosis	3001	amodiaquine analogues in	2654
Locked nucleic acid (LNA).....	77	antimalarial phenolics in	2655
applications <i>in vivo</i>	79	apicoplast metabolism in	2646
biomedical application of	78	approaches to control	2644
enzymatic method	80	atovaquone in	2648
for potential therapeutic applications	81	atremisinin in	2648
methods of.....	80	azithromycin in	2648
mixed chemical/enzymatic methods for.....	80	benzo- -carbolines in	2654
post-synthetic conjugation for.....	80	benzoylthiourea complexes in	2652
solid phase synthesis of	80	bis-quaternary ammoniums in	2655
synthesis of.....	80	-carbolines in	2654
Low diffusion gadolinium chelates	762	chalcones in	2655
Low molecular weight iron chelators	2704	chemosensitizers in	2653
effect of	2704	chemotherapy of	2647
effect on iron excretion/absorption	2704	chloroquine in	2647
Lower urinary tract (LUT).....	250	clindamycin in	2651
function of.....	250	combination therapy of	2650
Lymphatic invasion	3043	control of	2643
development of lymphatic vessels in	3443	cryptolepin in	2652
molecules involved in	3049	decahydroquinoline derivatives in	2653
pathways of	3050	diaminopyrimidines in	2652
role of lymphendothelial growth factors	3044	DNA vaccines in	2645
role of lymphendothelial transcription factors	3045	folate pathway in	2646
role of sentinel lymph node	3050	fosmidomycin in	2651
Macromolecules	1853	glycerophospholipids in	2647
photomechanical transdermal delivery of	1853	glycolytic pathway in	2646
Macromolecule SOC	1477	glycophosphatidyl inositol (GPI) in	2647
antibody recognition studies of	1477	halofantrin in	2648
Macromolecules SOCn-I,II	1474	heme metabolism in	2646
applications in vaccine development for human	1477	hexahydrodibenzopyrans in	2654
use	1477	hydroxamates in	2651
		immunotherapy in	2645
		isoquine in	2654
		lipid metabolism in	2647
		mefloquine in	2648
		mitochondrial electron transport in	2645
		NANP in	2645
		neocryptolepin derivatives in	2652

NYVAC-Pf7 in	2644	in atherosclerotic plaques	919
pathogenesis of	2643	in clotting	919
pentamidines in	2652	in coronary artery disease	917
peptidyl deformylase in	2647	in myocardial remodeling	922
peroxides in treatment of	2649	in remodelling	920
Pfs 230	2645	in stable coronary artery disease	919
proteases in	2646	in unstable coronary artery disease	921
pyrimidinyl peptidomimetics in	2653	in unstable plaque	922
quinine in	2647	mechanism of action of.....	342
role of genomics	2645	MMP-1.....	349
RTS in	2645	MMP-13.....	350
terpenes in	2655	MMP-2.....	349
thiolactomycin in	2651	MMP-3.....	350
thiopeptide antibiotics in	2651	MMP-7.....	350
use of antimalarial drugs	2647	MMP-8.....	349
use of circumsporozoite protein (CSP)	2644	MMP-9.....	349
use of SPf66	2644	pathological significance of	917
vaccination in	2644	role in angiogenesis	917
validated biochemical targets in	2645	structural studies of.....	343,351
vector control for	2644	substrate selectivity of.....	343,351
		variance/genetic polymorphisms of	921
Malaria parasite	2643	Matrix metalloproteinase inhibitors.....	339
life cycle of	2643	active site of.....	339
Malarial synthetic peptides	2849	conformational studies of.....	351
HLA-DR 1 allele binding specificities of	2849	effects of phosphonamide based hydroxamic	
in multi-component subunit-based synthetic		acids.....	347
vaccine	2852	effects of sulfonylated amino acid	
modified protection-inducing	2849	hydroxamates	347
TCR contacting residue orientation in	2849	effects of sulfonylated amino acid carboxylates ...	347
Manganese	2607,2746	nature of	339
mitochondrial dysfunction by	2607	pharmacophore mapping of.....	339
Mangiferin	2529	QSAR studies of.....	339,352
aglycon norathyriol of	2529	SAR results of.....	345,352
Many diverse scaffolds (FXR)	1063	structural studies of	343,351
medicinal chemistry of	1063	subclasses of	339
pharmacology of	1063	substrate selectivity of.....	351
MAP kinase p38 inhibitors	2979	Matrix turnover	917
AMG 548 as	2979	basic biochemistry of	917
binding modes of	2984	Medicinal plants	2625
BIRB 796 as	2980	inhibitory properties against snake venoms	2625
extended binders at	2989	Melanotransferrin	2715
interactions with p38 protein	2979	storage of	2715
linear binders at	2987	2-Mercaptobenzothioazoles (LXR)	1072
SCIO 323 as	2980	pharmacology of	1072
SCIO 469 as	2980	Mercaptopiperidines	555
selectivity of	2989	synthesis of	555
teardrop binders at	2984	Mercury	1194,2607,2775
VX 702 as	2982	and calcium	1196
Matrix metalloproteinases (MMP)	339,917,1273	as antioxidant	1195,1198
as prognostic/clinical indicators	920	effect on stress proteins	1197
biological implications of	341	immune functions of	1198
circulating type	920,922	in cardiovascular death	1196
clinical/therapeutic implications of	917	in differentiation of cells	1198
conformational studies of.....	351	in homeostasis	1198
effects of hydroxamates	345	in oxidative stress	1195
effects of phosphonamide based hydroxamic		in proliferation	1198
acids.....	347	in signaling	1198
effects of sulfonylated amino acid hydroxamates ...	347	neuroprotective/neurodegenerative role in	
effects of sulfonylated amino acid carboxylates....	347		
impact of drug therapies	923		

alzheimer's diseases	1200	in aging	429
neurotoxicity by	2607	in cancer	429
Metals	1162	in diabetes	429,438
AP-1/NF- κ B activation by	1162	in diseases	429
effect on DNA	1167	in heart failure	429
effect of lipids	1167	in heart failure models	433
effect on proteins	1169	in mitochondrial oxidative stress	434
in activation of signaling pathways	1162	in MPP ⁺ -induced Parkinson disease model	435
Metal compounds	2607	in neurodegeneration	429
Metal ion responsive contrast agents	767	in Parkinson's disease	434
in biological processes	767	<i>in vitro</i> effect of MPP ⁺ on replication of	436
Metastasis suppressor gene	2722	knockout mouse models of	433
Methoxylated xanthenes	2499	somatic mutation of	432
1-Methyl-4-phenylpyridinium (MPP)	2608	Mitochondrial dysfunction	1831
Methylene blue	2608	Mitochondrial electron transport chain	2602
MHC class 1	633	biological aspects of	2602
of peptides	633	Mitochondrial ferritin	2715
MHC class 11	633,1528	Mitochondrial GSH	2616
allele specific motifs of	1528	Mitochondrial oxidative phosphorylation inhibitor	2614
of peptides	633	Mitochondrial protein synthesis	2617
MHC-peptide-TCR complex	2854	and biogenesis	2617
structure of	2854	Mitochondrial respiratory stimulation	2614
Microbial host systems	1664	by protonophores	2614
expression of pathway genes in	1664	Mitochondrial ROS formation	2612
Microbial transcription factors	694	by monoamine oxidase activity	2612
Micro-HPLC (μ -HPLC)	573	by respiratory inhibition	2612
Migraine	1804	Mitochondrial targets	1833
altered immune responsiveness in	1804	leading to drug toxicity	1833
Milk protein-derived peptides	1915	Mitochondrial toxicity	1829,2612
application of	1915	by other drugs environmental toxins	2612
production of	1915	detection of	1829
scope of	1915	drug-associated	1829
Minor groove binder	2826	methods for assessment of	1835
basic structure of	2826	Mitochondrial toxin	2606
dimeric intercalators with	2835	quinones as	2606
functionalities of	2826	tryptamine-4,5-dione (T-4,5-D) as	2606
miRNAs	3145	Mitochondrial uncouplers	2601
dicer protein family of	3148	and radiation	2606
Mitochondria	1829	mechanism of	2601
drug-associated changes in m of	1835	role of reactive nitrogen species (NO/PN)	2606
function of	1829	structure-activity relationships of	2601
membrane potential m of	1834	Mitomycin C	2607
methods for assessing function of	1835,1836	induced nuclear damage	2607
structure of	1829	Mixed connective tissue disease (MCTD)	1476
techniques for monitoring drug effects on	1834	anti-Sm in	1476
Mitochondrial cell death signaling	2614	anti-U1RNP autoantibodies in	1476
Mitochondrial cytochrome/protein complexors	2612	Modular polyketides	1697
Mitochondrial DNA	429	biosynthesis of	1697
alterations in cancer	438	Monofunctional platinum complexes	2183
alterations of	429	Mucosal membrane	1853
anticancer drugs damage of	439	transport across	1853
as repair system for oxidative damage	431	Multiple epitope trojan antigen peptide vaccines	1487
in age-associated neurodegeneration	434	Multiple sclerosis (MS)	1513,1521,1543,1569,2947
		anti-CD3 MAb in	2952
		anti-CD4 MAb in	2952

anti-CD11 MAb in	2953	Myelin proteins	1569
anti-CD40 MAb in	2953	atomic level description of	1579
anti-CD52 MAb in	2953	composition of	1572
anti-IL-12 MAb in	2954	connexins of	1578
anti-inflammatory immunotherapy for	2947,2952	current status of	1569
anti- α 7 integrin MAb in	2954	function of	1569
anti- α 4 β 1 integrin MAb in	2954	in multiple sclerosis	1569
anti-TNF MAb in	2955	in PNS	1572
bioactive peptides in treatment of	1515	lipid composition of	1578
Ca ²⁺ homeostasis in	2949	MAG of	1577
combinational approaches to block		membrane of	1578
inflammation in	2956	molecular mimicry of	1579
cytokine-based immunointervntion by		myelin basic protein (MBP) of	1576
anti-cytoikne mAbs in	2954	myelin cyclic nucleotide-phosphodiesterase	
differences/similarities of	2948	(CNP) of	1578
etiology of	1570	myelin oligodendrocyte glycoprotein	
excitotoxicity in	2949	(MOG) of	1575
induction of regulatory cells in	2955	myelin oligodendrocytic basic protein	
MAB against chemokines in therapy for	2953	(MOBP) of	1575
MAB aganinst adhesion molecules in	2953	myelin protein 2 (P2) of	1574
MAB therapy directed against autoreactive T/		N-CAM of	1578
cells in	2952	periaxin of	1578
MHC in	1523	peripheral myelin protein-22 of	1574
molecular mimicry in	1524,1570	protein zero (PO) of	1573
myelin sheath in	1570	proteolipid protein (PLP) of	1575
pathology of	1570	S100 of	1578
peptides for interleukin-2 receptor (IL-2R)		structure/composition in CNS	1572
targeted therapy in	1544	structure of	1569,1572
peptides in	1543	Myelin specific epitopes	1579
targeting intracellular signaling pathways in	2955	structural approaches of	1579
use of animal models in treatment research of	1514	Myoglobin	2741
Multivalent compounds	1887	as pro-oxidant enzymes	2741
for antigen-specific B cell tolerance	1887	associated oxidative stress	2741
for antiphospholipid syndrome	1895	from molecular mechanisms to disease states	2741
for lupus	1892	pro-oxidant/pseudo-peroxidase activities of	2744
for treatment of autoimmune diseases	1887	redox/radical chemistry of	2741
for xenotransplantation	1898	<i>N</i> -Acetyl carnosine	2313
Multivalent platform molecules	1891	as carnosine derivative	2313
Muscarinic acetylcholine receptors	2915	<i>N</i> -Acetylcysteine	2785
action of	2915	<i>N</i> -acylphosphatidylethanolamine-hydrolyzing	
as targets of therapeutic approach	2917	phospholipase D	1413
in Alzheimer's disease	2915	<i>N</i> -Alkyl- <i>N</i> -phenylsulfonamides (LXR)	1067
mechanism of muscarinic signal transduction	2915	medicinal chemistry of	1067
physiological relevance of	2915	pharmacology of	1067
therapeutics of	2918	NAPE-PLD	1416
Muscarinic agonist	565	catalytic properties of	1416
in treatment of Alzheimer's disease	565	characterization of	1417
Muscarinic binding sites	2917	expression in animal tissues	1417
and cholinergic projections	2917	in cDNA cloning	1417
Myasthenia gravis	1476	recombinant enzyme by	1417
anti-AChR antibodies in	1476	Naphthoquinones	2607
MIR peptide in	1476	Natural antioxidant caffeic acid derivatives	1811
Myelin basic protein peptides	1521	as antiviral antioxidantes	1813
binding of	1521	an antiviral supplementation diet	1811
bound to MHC II molecules	1530	anti-HIV activities of	1811
effects on immune regulation	1521	bioavailability of	1815
structural basis of T cell recognition of	1530		
structural requirements for	1521		
with MHC II	1521		

metabolism of	1815	<i>N</i> -linked oligosaccharide	530
toxicity of	1815	synthesis of	530
Natural hydroxylated α -amino acids	3063	<i>N</i> -myc downstream regulated gene-1 (NdrG1)	2722
Natural phospholipases A ₂ inhibitors	2632	Non peptidic ν 3 antagonists.....	51
from plants	2632	recent developments of	51
studies on	2632	Non-anti-tumor activity of.....	130
Natural snake venom inhibitors	2626	Non-canonical peptide-MHC class 1 interaction	635
derived from plants	2626	Non-CB ₁ non-CB ₂ cannabinoid receptors ligands	1385
<i>N</i> -benzyl-2-2-diphenylethylamines (LXR)	1069	other types	1389
cross-reactivity to other NRs	1070	Non-classic bioisosterism	39
3D information of	1070	functional groups	39
medicinal chemistry of	1069	Non-classical anti-folate inhibitors (NCAI)	2253
pharmacology of	1070	Non-classical cannabinoids	1225
Neorx pretargeting technique.....	326	Non-classical platinum-based antineoplastic agents	2177
Netropsin	2805	design of platinum complexes for	2177
analogues of	2805	development of	2177
Neurokinin receptors	1246	for tumor-targeted cytotoxicity	2177
Neuropeptide-derived antimicrobial peptides	3055	role of DNA-binding pattern	2177
for cardiovascular diseases diagnosis	3059	Non-hydroxamate histone deacetylase inhibitors	2867
from invertebrates for biomedical applications		electrophilic ketones as	2871
of	3055	epoxyketones as	2869
maggots therapy by	3057	isozyme selectivity of	2876
neuroendocrine link of	3057	mercaptoamides as	2873
Neurotoxicity	559	<i>N</i> -formyl hydroxylamines as	2871
and tetrahydropyridine ring	559	<i>o</i> -aminoanilides as	2870
Neurotransmitters	1998	phosphones as	2875
choline of	1998	sulfones as	2875
thiocholine borane derivatives of	1998	thiols as	2872
Neutral endopeptidase	351	Non-peptide synthetic CRF antagonists	1510
structural studies of.....	351	in inflammatory diseases	1510
substrate selectivity of.....	351	therapeutic implications of	1510
Nickel	1184,2778	Non-receptor tyrosine kinases	1254
induced activation of transcription factors	1185	Non-ribosomal peptides	1697
induced carcinogenicity	1186	biosynthesis of	1697
in homeostasis	1184	Nonsteroidal antedugs	2236
in oxidative stress	1186	Non-steroidal anti-inflammatory drugs	
toxicity of	1184	(NSAIDs)	573,566,2936
Nitric oxide	2731	blood samples of	576
in pathological conditions	2731	determination in biological samples	584
mitochondrial damage due to	2732	development of	2936
Nitrofurans	2609	in biological samples	573
3-Nitropropionic acid (NPA)	2610	in blood	573
Nitrosative stress	267	in erythrocytes	573
as therapeutical strategies.....	267	in pharmaceutical formulations	573
role of.....	267	in plasma	573
in pathogenesis of diabetic cardiomyopathy.....	271	liquid-liquid extraction (LLE) of	576
in pathogenesis of diabetic complications	267	sample pretreatment of	573
implications of.....	273	solid-phase extraction (SPE) of	576
in pathogenesis of diabetes-induced vascular		use of capillary electrochromatography (CEC) ...	575
dysfunction	267	use of capillary electrophoresis (CE)	575
in pathogenesis of diabetic retinopathy/nephropathy/		use of capillary electrophoresis/capillary	
neuropathy.....	273	electrochromatography coupled to mass	
Nitrosopropofol	2609	spectrometry	573
		use of μ -HPLC in (CE-/CEC-MS)	575
		use of HPLC-UV-MS	573
		use of liquid chromatography	574

use of liquid chromatography coupled to mass spectrometry (LC-MS)	574	in cancer	359
use of reversed phase high-performance liquid chromatography (RP-HPLC)	577,578	in human disease.....	357
use of thin-layer chromatography (TLC)	574	in inflammatory diseases	358
use of UV-spectrometry	574	in neurodegenerative disorders.....	359
Non-steroidal steroid receptor	1017	in viral diseases.....	359
modulators of	1017	inhibitors of	357
Non-steroidal subtype selective estrogens	1077	prospects for.....	357
Novel 5-FU derivatives	1433	structure based <i>de novo</i> design of	368
lipophilicity of	1433	Nucleic acid binder	2114
Novel nucleoside prototype	1423	synthesis of	2114
<i>N</i> -Phenylbenzyl amides (FXR)	1061	Nucleic acid intercalator	2112
cross-reactivity to other NRs	1062	synthesis of	2112
3D information of	1063	Nucleotide deoxysugars	1637
medicinal chemistry of	1061	as tools for glycosylation engineering	1637
pharmacology of	1062	chemical synthesis of	1642
NS3 protease inhibitors	2317	chemo-enzymatic synthesis of	1643
as therapeutic agents against HCV infection	2317	expression in <i>Escherichia coli</i>	1663
biological activity of	2326	for novel bioactive compounds	1637
cytotoxicity assays of	2333	inclusion body problem with	1663
discovery of	2317	Obesity	2215
enzyme inhibition assay of	2331,2333	adipose tissue apoptosis in	2216,2218,2219
enzyme selectivity of	2333	ajoene in	2221
HCV replicon assay of	2331	apoptotic agents in	2218
<i>in vivo</i> target tissue drug exposure	2331	apoptotic pathways in	2217
targeting NS3-NS4A interaction by	2319	bone marrow adipogenesis in	2216
<i>N</i> -substituted pyridones (LXR)	1065	conjugated linoleic acid in	2220
medicinal chemistry of	1065	death receptor pathway in	2217
pharmacology of	1065	effect of natural compounds	2219
<i>N</i> -substituted quinazolinones (FXR)	1065	(-)-epigallocatechin gallate (EGCG) in	2220
medicinal chemistry of	1065	flavonoid compounds in	2219
pharmacology of	1065	in humans	2215
Nuclear envelope	1842	mitochondrial pathway in	2218
transport through	1842	molecular mechanisms of apoptosis in	2217
Nuclear hormone receptors	1258	novel treatments for	2215
Nuclear receptors (NRs)	1001	targeting apoptotic pathways in adipocytes in	2215
agonist/antagonist positions at	1007	Octahydro-2 <i>H</i> -naphto-[1,2-]-indazoles	1032
cofactor-binding groove of	1002	cross-reactivity to other NRs	1032
dimerization of	1002	medicinal chemistry of	1032
dimers of	1012	pharmacology of	1034
family-based structure analysis of	1001	Olefinic polyamide nucleic acids (OPAs)	2575
family specific cofactor-binding residues for ...	1011	Oligodendroglial excitotoxicity	2951
family specific LBP residues of	1007	to demyelinating disorders of CNS	2951
H12/ligand-binding residues of	1005	Oligonucleotides	71,781
ligand binding at	1007	approach for cancer treatment	71
ligand-binding domain of	1001	chemically modified	781
ligand-binding pocket of	1002	conjugates of.....	81
ligands of	1004	modulation of transport of	783
role of coactivator-binding residues	1009	non-antisense interactions of	784
role of cofactors	1009	with anti-cancer drugs.....	81
Nuclear-factor kappa B (NF-κB).....	357	Oligonucleotide conjugates.....	71,79
activation of	357	approach for cancer treatment.....	71
current inhibitors of.....	360	with anti-cancer drugs.....	81
<i>de novo</i> structure based design of inhibitors of.....	357	Oligonucleotide-platform conjugates	1893
DNA binding inhibitors of	368	Oligosaccharide	536
DNA binding of	357	coupling of	536

structural analysis of	543	in brain tumors	1599
with peptide	536	in breast carcinomas	1597
Oncogene	1777	in endocrine tumors	1599
KIT as	1777	in epithelial tumors	1597
MET/HGFR as	1777	in gastrointestinal tract	1598
RET as	1778	in larynx/oral cavity carcinomas	1599
Onset atrial fibrillation	1334	in liver carcinomas	1598
development of	1334	in lung carcinomas	1598
Ophidian envenomation	2626	in lymphomas	1599
alternative treatments for	2626	in ovarian/cervix carcinomas	1598
Opioid receptors	1246	in prostate carcinomas	1598
Optimal antisense sequence.....	72	in soft tissue sarcomas	1599
Osteoporosis	2215	knock-out model of	1595
adipose tissue apoptosis in	2218	molecular basis for targeting in human cancers	1600
ajoene in	2221	regulation of	1592
apoptotic agents in	2218	role in G2-M transition	1592
apoptotic pathways in	2217	transcriptional regulation of	1592
bone marrow adipogenesis in	2216,2219	P^{38} mAP Kinase	1253
conjugated linoleic acid in	2220	p^{38}	2982
death receptor pathway in	2217	requirements for inhibition of	2982
effect of natural compounds	2219	Paramagnetic hepatobiliary contrast agents	2799
(-)-epigallocatechin gallate (EGCG) in	2220	gaobenate dimeglumine as	2800
flavonoid compounds in	2219	gadofosveset trisodium as	2802
mitochondrial pathway in	2218	Gd-EOB-DTPA as	2801
molecular mechanisms of apoptosis in	2217	ferucarbotran C as	2802
novel treatments for	2215	mangafodipir trisodium as	2799
targeting apoptotic pathways in adipocytes in	2215	Paraquat	2608
Oxacyclic <i>O,N</i> -acetals	1423	Partial oxygen pressure pO ₂ responsive contrast	
against molecular markers	1434	agents	774
and apoptosis markers	1435	in strokes	774
anticancer activities in human breast cancer		in tumors	774
MCF-7 cell line of	1434	Passive reporter molecules	839
antiproliferative activities of	1434	Pelvic floor disorders.....	247
antiviral activities of	1425	botulinum neurotoxin.....	247
apoptosis induction of	1434	constipation due to.....	258
biological activities of	1423	management of.....	247
cell cycle distribution of	1434	Pendred syndrome	393
in anticancer therapy	1425	SLC26A4 mutations in	393
in breast cancer	1426	Pentachlorophenol	2610
inter-molecular interactions of	1429	Peptide-based vaccine design	629,1481
modification of molecular markers by	1435	and MHC polymorphism	632
morphological changes in MCF-7 treated		antigen selection in	631
cells by	1436	bioavailability in	636
open analogues of	1423	carbohydrate antigens in	1489
Oxidative stress	1161,2647	class I processing of	1482
in infected erythrocytes	2647	class II processing of	1482
role of metals	1161	cryptic epitopes for	1486
toxicity in	1161	cryptic peptides in	632
p27 mutants	1601	current clinical trials of	631
gene therapy approach in cancer using	1601	effective immune response by	631
p27 kip1	1589	enhanced proteolytic stability of	636
as target of proteasome	1592	for cancer immunotherapeutic applications	629
as tumor suppressor gene	1595	for cancer immunotherapy	1481
effect of proteasome inhibitors	1600	incorporation of non-natural amino acids in	637
effects in human tumors	1597	non-natural peptides in	1488
functional inactivation of	1594	peptide ligands as agonists in	636
gene therapy approach in cancer using	1601	presentation pathway of	1482
		quality of immune response due to	631

retro-inverso peptides in	636,1488	in pancreatitis	3003
T cell activation in	1489	in rheumatoid arthritis	3003
Peptide cyclization	1487	in skin inflammation	3002
Peptide-MHC II	1525	inhibitory interactions with transcription	
binding mechanism for	1525	factors	2999
T-cell receptor recognition of	1525	interactions with co-regulators	2999
Peptide-MHC interactions	633	molecular mechanisms of	2998
Peptide nucleic acid (PNA)	74,2561,2840	regulation of kinase activity	2999
advantages of	2563	Peroxynitrite-poly (ADP-ribose) polymerase.....	273
alternative nucleobases for	2591	in pathogeneois of diabetic complications.....	273
and metal complex conjugates	2585	Peroxynitrite.....	267
and related nucleic acid base linked polymides .	2840	as therapeutical strategies	267
backbone modifications of	2573	implications.....	273
chemical overview of	2561	improves cardiac/vascular dysfunction of diabetes	272
comparison with native nucleic acids	2563	in pathogenesis of diabetic complication.....	267
containing non-standard nucleobases	2591	role of	267
disadvantages of	2563	pH responsive contrast agents	769
DNA chimeras	2566	in tumors	769
limitations of.....	75	Phenols	2609
modified type	2566	3-Phenoxy-2-hydroxy-2-methyl- <i>N</i> -(phenyl)	
properties of	2562	propionamides.....	1054
solid phase synthesis of	2565	cross-reactivity to other NRs	1055
synthesis of	2563,2589	medicinal chemistry of	1054
synthesis of monomers of	2564	pharmacology of	1055
therapeutic applications of.....	75	6-Phenylquinolines	1036
with bipyridine ligands	2585	cross-reactivity to other NRs	1037
with five/six-membered cyclic structures	2579	medicinal chemistry of	1036
Peripheral arterial disease (PAD)	443	pharmacology of	1037
and endothelial function	448	Pheromone biosynthetic enzymes	463
and myocardial ischaemia	445	Phosphate isosteres	3127
and re-infarction	445	in medicinal chemistry	3127
cardiological interventions in	444	miscellaneous type	3137
coronary events in	445	Phosphorus-based isosteres	3128
effect of CRP	448	non-phosphotyrosine targets of	3132
effect of fibrinogen	447	phosphotyrosine mimetics to	3128
effect of homocysteine (Hcy)	448	Photoaffinity labeling technique	652
effect of lipoprotein.....	448	application in cellular extracts	652
effect on renal function	447	Photoaffinity modification	647
emerging risk factors of	447	of DNA repair proteins	647
in diabetes mellitus (DM)	445	of purified DNA replication proteins.....	647
in insulin resistance	445	Photodynamic therapy (PDT)	1210
peripheral vascular surgery in	445	principles of	1210
risk of stroke in	445	Photoecdysteroids	153
role of lipids	445	antioxidant effect of	165
role of platelet inhibition	445	as antiarrhythmic	165
role of statins	443,448	carbohydrate metabolism stimulation by.....	163
to reduce cardiac morbidity/mortality in	443	difficulties in isolation of.....	162
Peroxisome proliferator-activated receptors (PPARs) ..	2995	effect on humans	153
and adhesion molecules	3000	effect on lipid biosynthesis	163
and chemokines	3000	effect on renal dysfunction	164
and inflammation-related diseases	2999	effect on urea balance.....	164
and vascular smooth muscle cells	3000	extraction/prepurification of	159
control mechanisms of inflammation	2995	gene regulation system.....	167
dependent anti-inflammatory responses	2998	hepatoprotection by.....	164
in atherosclerosis	2999	immunostimulant effect of.....	165
in cancer	3004	in treatments of humans.....	166
in diseases	2995	inducible mammalian expression system.....	168
in gastritis	3002		
in inflammatory bowel diseases	3001		
in nephropathy	3003		
in neurodegenerative disorders	3003		

isolation of.....	153	Platinum complexes	2178,3095
low toxicity of.....	165	as telomerase inhibitors	3095
model system for PCD.....	170	cationic complexes without leaving groups at ..	2183
molecular mechanisms of action of.....	167	cellular pharmacology of	2178
on-line spectroscopic analysis of.....	162	with trans-geometry	2180
other effects of.....	165	with tumor tissue-targeted cytotoxic action	2187
pharmacological effects of.....	163	Platinum (IV) complexes	2079
physiological effects of	163	derivatization of	2079
production scale isolation of.....	159	peripheral functional groups at	2079
prospects in genomic drug discovery.....	167	Platinum coordination compounds	2179
pruification by low-pressure chromatography.....	159	with cisplatin-dissimilar DNA-interactions	2179
purification by repeated LCHPLC.....	161	Plecomacrolides	1947
Photofirin II	1209	structures of	1947
application of	1209	total syntheses of	1947
as radiosensitizer	1210	pMHC binding groove interface	1484
as sensitizing agent for	1209	influence of water at	1484
clinical applications of	1213	pMHC interactions	1482
in ionizing radiation	1209	pMHC class I interactions as	1482
in tumor therapy	1209	pMHC class II interactions as	1484
<i>in vitro</i> studies of	1210	<i>via</i> anchor residue modification	1486
<i>in vivo</i> studies of	1211	PNA-DNA duplex	2585
mechanism of radiosensitizing activity of	1212	modified naphthalene diimide with	2585
Photoreactive DNAs	643	PNA-peptide	2569
properties of	643	Poly(ADP-ribose)glycohydrolase (PARG)	2385
synthesis of	643	Poly(ADP-ribose)polymerase	2373
Physiological lymphangiogenesis	3043	chronic inhibition of	2382
in embryonic development	3044	inhibition of	2373
in wound healing	3044	selective inhibition of	2383
regeneration as	3043	Polyaminopolycarboxylic acids	2786
role of lymphendothelial growth factors	3044	Polychlorinated biphenyls (PCBs)	2611
role of lymphendothelial transcription factors ..	3045	Polyhalogenated arylhydrocarbons (PAHs)	599,2611
Phytopharmaceutical	931	effect on female gametogenesis	602
Piperidine ring	555	effect on folliculogenesis	602
modification of	555	effect on ovarian function	602
<i>Plasmodium falciparum</i>	2849	effect on sex steroid actions	600
invasion by	2851	in female reproduction	599
molecular approach to invasion process of	2856	in female reproductive tract	600
reproduction cycle of	2850	in mammary gland development	608
Platelets	3117	in uterus	606
activation of	3119	mediated disregulation of hypothalamus	
adhesion of	3119	pitutaryovarian axis	605
aggregation of	3120	molecular actions of	599
assessment of	3117	molecular actions during mammary gland	
indirect methods of studying	3132	neoplasia	608
methods of studying	3121	ovotoxic potential of	606
pharmacological intervention of	3121	Polynuclear platinum complexes	2181
secretion of	3120	Porphyrins	1210
structure of	3117	analogues of	1210
use of electron microscopy	3121	as potential radiosensitizers	1210
use of flow cytometry	3121	Positron emission tomography (PET)	807,2057
Platelet activation	3117	as molecular imaging tool	2058
in antiplatelet drug development	3117	for α -adrenoceptor radioligands	2065
Platelet microparticle	3120	Positron emitting isotopes	807
as pharmacological target	3120	applications of ^{45}Ti as	809
Platinum	2607,2778	bromine-76 as	812
induced apoptosis	2607	carbon-11 as	809
Platinum based drugs	3091		
as anti-telomerase pharmacological approach ..	3091		

copper-60-61-64 as	810	computational studies of	736
fluorine-18 as	809	estrogenic activity of	724
halogens as	812	from Euphorbiaceae	720
iodine-124 as	812	from Guttiferae	720
nitrogen-13 as	809	from Leguminosae	717
oxygen-15 as	809	from Moraceae	713
radiolabeling studies using ⁴⁵ Ti as	809	from Umbelliferae	720
titanium-45 as	809	in apoptosis	726
Positron emitting radionuclides	809	in biotechnology `	713,730
Post assembly peptide modifications	849	in multidrug resistance	723
backbone modifications in	867	induction of quinone reductase by	726
based on radical reactions	858	inhibition of human P ₄₅₀ enzymes by	727
by chemical methods	849	pharmacology of	713,723
by cross coupling reactions	851	structure-activity relationship studies of	729
by cyclization route	862	Prenylated hexa-oxygenated xanthenes	2441
by cycloaddition reaction	854	Prenylated mono-oxygenated xanthenes	2422
by formation of , -dehydropeptides	849	Prenylated penta-oxygenated xanthenes	2441
by oxidation reaction	855	Prenylated tetra-oxygenated xanthenes	2439
miscellaneous approaches for	867	Prenylated tri-oxygenated xanthenes	2422
Postprandial lipaemia	1931	Prenylated xanthenes	2422,2487,2513,2530
and cholesterol homeostasis	1934	from <i>Garcinia mangostana</i> L	2530
circadian differences of	1936	8-Prenylnaringenin	724
clinical relevance of	1931	Prenyltransferase	734
gender differences of	1936	from <i>Morus nigra</i> cell cultures	734
hormone replacement therapy (HRT) of	1941	from <i>Sophora flavescens</i> cell cultures	734
in diabetes mellitus	1936	Pretargeting	324
in metabolic syndrome	1936	animal/clinical studies of	326
in obesity	1936	avidin in	324
role of diet	1939	with avidin biotin recognition system.....	324
role of exercise	1939	biotin derivatives in	325
statin-fibrate combination treatment of	1940	chase agents in	324
treatment of	1939	effect of endogenous biotin	326
use of fibrates	1939	labeled molecules in.....	324
use of fish oils	1940	of receptor peptide ligands.....	334
use of nicotinic acid	1940	streptavidin in	324
use of orlistat	1940	three step protocol of.....	327
use of statins	1940	Pri-amine compounds	2608
PPAR	1261	Privileged scaffold	877
PR modulators	1017	(3 <i>H</i>)-benzoxazolone as	877
tetrahydropyridazines (THP) as	1017	bioisosters as	877
Pregnancy	1767	in design of pharmacological probes	877
therapeutical approaches during	1767	Pro-antidugs	2237
Prenylated di-oxygenated xanthenes	2422	Procainamide	2609
Prenylated flavanones	727	Progesterone receptor	1017
computational studies of	736	modulators of	1017
enzyme localization of	736	Proliferation markers	814
of sophora	727	Proline-specific dipeptidyl aminopeptidases	971
partial characterization of	736	inhibitors of	971
Prenylated flavonoids	713	therapeutic perspectives of	971,993
activities of	722	Propofol	2609
acyltransferase inhibition by	726	Prostaglandin I ₂ - induced cyclic AMP formation	1309
and aromatic prenyl transferases	733	reduction by arachidonic acid of	1309
and flavonoid prenyltransferase	733	Prostaglandin receptor antaonist	2531
and prenyltransferase	732	AH6809 as	2531
as antioxidant	726		
as cancer chemopreventive anticarcinogen	726		
as promoter for nerve growth factor	726		
biotransformations of side chain of	730		

Prostaglandins E ₂ /F ₂	1309	PTP inhibitors.....	5
Prostate cancer	1623	3-acyl tetronic acid derivatives as	16
inhibition of P450 17 in	1623	aromatic phosphates as.....	11
strategy for	1623	aryloxymethyl phosphonates as.....	13
treatment of	1623	azolidinediones as.....	14
Prostatic disorder.....	247	azimidazole derivatives as.....	17
management of.....	247	benzofuran as	16
Proteases	1263	benzothiophene biphenyls as.....	16
Protease inhibitors	592	fluorine-containing peptides as.....	6
and active site titrants	592	-halocetophenone derivatives as.....	16
Proteins	1573,2683	heterocyclic monocarboxylic acid inhibitors as.....	18
in cellular iron uptake	2684	indolyldihydroxy quinones as.....	18
in iron binding	2691	isoquinoline as.....	13
in iron storage/release	2686	natural products as.....	17
in iron storage/transport	2683	natural product analogs as	17
in regulation of cellular iron homeostasis	2686	OMT-containing peptide inhibitors as.....	6
myelin oligodendrocyte glycoprotein (MOG)		oxamic acid-based inhibitors as.....	7
of	1575	peptidic - ketocarboxylic acid derivatives as.....	18
of CNS myelin	1575	peptidyl aldehydes as.....	6
of compact myelin	1573	peptidyl carboxylic acid inhibitors as.....	5
of non-compact myelin	1576	periodinates as.....	16
of PNS myelin	1573	phenanthredione derivatives as.....	13
structure/function of	2683	phthalazine diones as.....	13
Protein carriers	1469	PMP as.....	6
Protein kinases	1252	quinoline as.....	13
design of	1252	salicylic acid analogs as.....	13
synthesis of targeted compound libraries of	1252	steroid derived inhibitors as.....	16
Protein superfamily	1239	sulfotyrosyl as.....	13
design of	1239	Purine-based scaffolds	1255
for lead identification	1239	Pyranoxanthenes	2458
miscellaneous targeted libraries of	1275	Pyrazole derivatives	1230
optimization of	1239	Pyrazolo[[4,3-E]-1,2,4-triazolo[1,5-C]pyrimidines	1322
synthesis of	1239	as human A ₃ adenosine receptor antagonists	1322
targeted chemical libraries	1239	Pyrazolo[4,3-E]1,2,4-triazolo[1,5-C]pyrimidine	
Protein tyrosine phosphatase (PTP).....	1	ligands.....	1319
Cdc25 as	3	characterize A ₃ adenosine receptors in human	
classical	1	tumor cell lines by	1319
classification of.....	1	Pyruvate	2756
diseases linked with.....	4	QSRR	503
domain-containing classical.....	3	based on molecular interaction energy values	509
dual-specificity.....	3	calculation of logP for	503
inhibitors of.....	1,5	calculation of pK _a for	507
intracellular classical	2	in reversed-phase liquid chromatography	508
low molecular weight.....	3	Quassinoids	173
mechanism of catalysis of.....	4	antifeedant activity of.....	186
PEST-containing classical	3	antimalarial activity of	184
PT1P1B as	2	antitumor activity of.....	184
receptor-like classical	1	as leads for drug design.....	173
SHP-1.....	3	biological activities of.....	184
SHP-2.....	3	biologically active	173
VHR/MKPs/PTEN type	3	biosynthesis of.....	176
Prussian blue	2785	chemistry of.....	173
Pseudo complementary PNAs	2593	future prospects of.....	188
Psorospermin	2529	insecticidal activity of.....	186
as topoisomerase poison	2529	isolation of.....	173
Psychiatric disorders	1804	other biological activities of.....	186
altered immune responsiveness in	1804	quantitative structure-activity relation-ship	

(QSAR) study of	188	¹¹ C]methyl iodide as	2067
semisynthesis of.....	182	¹¹ C]phosgene as	2065
sources of.....	175	Radionuclide related factors.....	321
structure elucidation of.....	173	and target related factors	320
structure-activity relationship (SAR) of	186	Radionuclide therapy	788
total synthesis of.....	183	genetic modification of	788
Quinone methide	2894	Radiopharmaceutical chemistry	2057
by thermal generation	2898	Reactive nitric species (RNS)	1859
formation by enzymes/oxidations	2895	effect of DEP-1	1868
formation by fluoride induction	2898	effect of LMW-PTPS	1866
formation by reduction	2894	effect of PTEN	1867
formation induced by light	2897	effect of PTP-PEST	1867
formation of	2894	effect of PTP1B	1868
formation through isomerization	2898	effect of PTP	1868
react with nucleobases	2899	effect of SHP-2	1867
react with phosphate	2902	effect of PTP	1868
Quinone methide derivatives	2893	effects on activity of PTPS	1863
as intermediates to DNA alkylating/DNA		endogenous production of	1859
cross linking actions of	2893	mast cells as target for	1862
Quinoxaline 1,4-dioxide	2259	Reactive oxygen species (ROS)	429,1859
activities of	2259	effect of DEP-1	1868
antibacterial activity of	2261	effect of LMW-PTPS	1866
antimycobacterial activity of	2263	effect of PTEN	1867
anti-protozoal/anti- <i>candida</i> activities of	2266	effect of PTP1B	1868
as scaffold	2259	effect of PTP-PEST	1867
Beirut reaction at	2268	effect of PTP	1868
chemistry of	2267	effect of PTP	1868
growth-promoting properties of	2259	effect of SHP-2	1867
hypoxia-selective activity of	2264	effects on activity of PTPs	1863
mutagenic properties of	2261	endogenous production of	1860
photo-protective effects of	2264	mast cells as target for	186
preparation of	2268	production of	429
toxicity of	2259	Receptor-dependent delivers	1845
Quorum sensing inhibition	3103	charge dependant-mechanical	1846
Quorum sensing inhibitors	3105	EGF-receptor endocytosis for	1845
identified by focused screening	3105	human insulin receptor (HIR) based	1846
identified by random screening	3112	octreotide mediated	1845
Radioimmunotherapy	319	receptor-independent (nucleic acid transfections)	
affinity of.....	320	based	1846
animal studies of.....	326	transferrin mediated uptake for	1845
clinical trials of.....	333	Receptor-like classical PTPs (RPTPs).....	1
factors influencing targeting efficacy of.....	319	receptor-like classical present in.....	1
in animal models	333	Receptor tyrosine kinases	1254,1773
physical parameters for.....	321	as targets for anticancer therapeutics	1773
pretargeted.....	319	based cancer therapy with small-molecule	
pretargeting approaches towards.....	323	inhibitors	1775
radiochemical parameters for.....	322	gene amplification of	1775
rationale for pretargeting in.....	323	genomic rearrangements of	1773
recent advances in.....	319	in molecular resistance formation	1776
role of vector.....	320	oncogenic signalling by	1773
target density in.....	320	point-mutations of	1774
targeting specificity in	320	small molecule inhibitors based	1775
Radiolabeling synthon	2065	5 -Reductase	930
¹¹ C]acetone as	2065	nonsteroidal inhibitors of	934
¹⁸ F]fluoroacetone as	2069	steroidal inhibitors of	930
¹⁸ F]fluoroethyl derivatives as	2071	5 -Reductase inhibitors	927
¹⁸ F]fluoroisopropyl derivatives as	2070	4-azasteroids as	932
[2- ¹¹ C]isopropyl iodide as	2067	6-azasteroids as	934

benzoquinolizone derivatives as	934	RNA-induced transcriptional silencing (RITS)	
chemistry of	927	complex	3149
in prostate cancer	929	Rotenone	2611
pharmacological activity of	927,937	Salicylic acid	2609
recent advances in	927	Sars-coronavirus inhibition	2140
synthesis of	937	by tats	2140
Refractory anaemias	2665	implication for	2140
transfusional iron overload in	2665	Secretory phospholipase A ₂ group IIA	3011
Regulatory/accessory HIV-1 proteins	741	inhibitors in human clinical trials	3017
as targets for HIV-1 vaccines	741	inhibitors of	3011
as vaccine targets	745	preclinical studies of	3014
CTL responses directed against	742	Selenium compounds	2611
role in HIV-1 infection	741	Semantic clustering	1155
Remnant-like particle (RLP)	1931,1935	improve drug target by	1155
Renin-angiotensin-aldosterone system	1333	in discovery processes	1155
effects of inflammatory responses	1336	of genes differentially expressed in apoptotic	
in atrial fibrillation	1333	neurons	1155
Renin-angiotensin system block	1331	role for thyroid hormone	1158
and atrial fibrillation	1331	role in fatty acid metabolism studies	1157
Retroisosterism.....	46	role in ion homeostasis studies	1158
Reversed phase high performance liquid		Serine proteases	1273
chromaography (RP-HPLC)	573	Serine-threonine kinases	1253
Rheumatoid arthritis (RA)	1539	Serotonin transporter	2393
cytokines in	1540	classical QSAR of	2398
peptides in	1540	SERT uptake assay of	2394
perspectives in	1540	Severe acute respiratory syndrome (SARS)	2095
therapies for	1540	antiviral chemotherapy of	2095
Ribonucleotide reductase	2719	gradient-selected HMBC (gs-HMBC) 2D ¹ H	
molecular targets in addition to	2719	NMR/ ¹³ C NMR spectroscopy of	2100
Ribonucleotide reductase inhibitors	1283	synthesis of novel test compounds for	2095
as target in anti-tumour therapy	1283	Sialylglycopeptide	527
Ribozymes	2197	on solid phase	527
Ricin	667	synthesis of	527
as biological warfare agent	678	Signal transducers and activators of transcription	
development of potential inhibitors of	681	(STAT)	1819
mechasmus of action of	679	as new molecular target	1819
medicinal chemistry of	667	in acute inflammatory disease	1820
signs/symptoms of	679	in AIDs	1821
Ring bioisosteres.....	31	in asthma	1821
Ring closing metathesis (RCM) reaction	862	in atherosclerosis	1822
cyclization of peptides <i>via</i>	862	in celiac disease	1822
RNA imaging	779	in chronic inflammatory bowel disease (IBD) ...	1822
basic research of	779	in chronic inflammatory diseases	1820
in diagnosis	779	in diabetes	1822
RNA interference	2197,3143	in gluten-sensitive enteropathy	1822
as gene-specific approach	3143	in ischemia/reperfusion (I/R) injury	1820
as tool functional genomics	3157	in psoriasis	1822
design of	3151	in rheumatoid arthritis (RA)	1822
for molecular medicine	3143	role in pathologies	1820
in cancer therapies	3156	target for anti-inflammatory treatment	1819
in infectious diseases	3156	Silica	2608
in neurodegenerative diseases	3156	inflammation by	2608
mechanistic aspects of	3145	Simple coumarins	887
therapeutic applications of	3155	as anticancer	908
RNA-induced silencing complexes (RISC)	3148	as anticoagulant	910

as anti-inflammatory	910	Snake venoms	2630
as antimicrobial	908	plants with inhibitory properties against	2630
as antioxidant	910	SOCn-II carrier	1474
as antiviral	908	applications in vaccine development for	
as molluscicidal	908	human use	1477
biological activity of	887,907	biological studies of	1475
biscoumarins as	888	conformational analysis of foldamer	1474
cardiovascular effects of	910	mylopeptides in	1477
central nervous system (CNS) effects of	910	Solid state-X-ray crystallography	1554
enzyme inhibition by	909	V ₃ conformational studies in	1554
form nitro-/azidocoumarins	907	Soluble paramagnetic chelates	2795
from alkylcoumarins	907	Solution-NMR spectroscopy	1554
from arylcoumarins	906	V ₃ conformational studies in	1554
from coumarincarboxylic acids/analogues	907	Somatostatin receptors	1246
from formylcoumarins	907	Sophoraflavanone G	727
from halocoumarins/analogues	907	Specific R ₁ binding inhibitors	1289
from hydroxy/alkoxycoumarins	906	Specific R ₂ binding inhibitors	1288
from Knoevenagel reaction	900	Statins	443
from Kostanecki-Robinson reaction	902	and endothelial function	448
from Pechmann reaction	900	and myocardial ischaemia	445
from Perkin reaction	900	in diabetes mellitus (DM)	445
from Reformatsky reaction	903	in insulin resistance	445
from thiocoumarins	906	to reduce cardiac morbidity/mortality in	443
from Wittig reaction	902	Steroidal antedrug design	2230
identification of	898	chemical approaches to	2230
in medicinal chemistry	887	evaluation of	2234
methods of synthesis of	898	Steroidal antiandrogens	927
natural occurrence of	888	chemistry of	927
occurrence of	887	in prostate cancer	929
other applications of	910	pharmacological activity of	927,937
prodrug strategy of	910	recent advances in	927
separation of	898	synthesis of	937
synthesis from classic/non-classic methods	900	Stratum corneum	2274
synthesis of	887,905	lipid composition of	2274
triscoumarins	888	lipid organization of	2274
Simple di-oxygenated xanthenes	2415	role of IR/Raman spectroscopy	2277
Simple hexa-oxygenated xanthenes	2415	role of X-ray diffraction	2279
Simple mono-oxygenated xanthenes	2415	Streptomyces	1700
Simple non-oxygenated xanthenes	2415	genome of	1700
Simple penta-oxygenated xanthenes	2415	in evolution of secondary metabolite clusters ...	1700
Simple tetra-oxygenated xanthenes	2415	Stress-induced modulation	1803
Simple tri-oxygenated xanthenes	2415	of immune response	1803
Simple xanthenes	2415,2447,2482	Stress-related disorders	1801
classical methods for synthesis of	2447	drug targets in	1801
dicer protein family of	3148	Substituted amides (LXR)	1067
<i>in vivo</i>	3153	medicinal chemistry of	1067
reactivity of	2472	pharmacology of	1067
siRNAs	3148	Succinimides	1051
synthesis of	2447	cross-reactivity to other NRs	1052
Skin permeation enhancers	2280	medicinal chemistry of	1051
hydrophobic chain structure of	2280	pharmacology of	1052
structure-activity relationships of	2280	Sulfonamides	1233
SLC26 genes	385	Superoxide	2731
in human disorders	385	activation of uncoupled proteins by	2732
SLC26A5.....	386	as initiator of mitochondrial damage	2731
in non-syndromic hearing loss	386		
Small molecule antagonists	1457		

in pathological conditions	2731	regulation of	2022
mitochondrial damage due to	2732	regulation of uptake of	2035
Superparamagnetic iron oxides (SPIO)	2798	release of	2022
Synthesis	2541, 2544, 2546	thermoregulation by	2027
of 3,6-bis-(5-morpholinopentyloxy)xanthone ...	2544	transport of	2022
of 4-chloro-3,6-BIS-(-diethylaminohexyloxy)		Taurine analogues	2021
xanthone.....	2546	anti-aggressive behaviour by	2027
of 2,3,4,5,6-pentahydroxyxanthone	2541	anti-cancer activity of	2033
Synthetic carriers	1469	anti-cynide action of	2035
applications in vaccine development for		anti-microbial activity of	2033
human use	1477	as anti-alcohol	2032
biological studies of	1475	as anti-inflammatory	2031
characterization procedures of	1473	as anti-oxidation	2031
conformational characterization studies of	1474	as promoter of bile salts formation	2032
myelo peptides in	1477	inhibition of connexin 26 containing channels	
purification of	1473	by	2035
SOCn-I as	1469	cardiovascular activity of	2029
SOCn-II as	1469	in bone metablism	2034
synthetic aspects of	1473	in hepato-protection	2033
Synthetic hydroxylated -amino acids	3066	in retinal protection	2028
by functionalization of ring double bond	3066	in spectrum of biological actions	2024
by transformation of function groups	3072	muscular-activity of	2027
Synthetic vaccines	1469	neurological actions of	2024
Systemic lupus erythematosus (SLE)	1476,1541,1892	regulation of taurine uptake by	2035
anti-Sm in	1476	retrospect/prospects of	2021
anti-U1RNP autoantibodies in	1476	therapeutics of	2021
cytokines in	1541	thermoregulation by	2027
peptides in	1542	T-cell receptors (TCR)	2855
perspectives in	1542	TcR-pMHC interactions	1484
therapies for	1542	via Up residue modification	1486
Taurine	2021	Techneium	815
abnormalities by	2022	chemistry of	815
accumulation of	2022	Telomerase	3091
anti-aggressive behaviour by	2027	architecture of	3091
anti-cancer activity of	2033	biology of	3091
anti-cynide action of	2035	for cancer diagnosis/prognosis	3094
anti-microbial activity of	2033	Temperature responsive contrast agents	774
as anti-ageing	2034	Terpenoids	1295
as anti-alcohol	2032	classification of	1295
as anti-diabetic	2034	Tetrahydro-[1,4] oxazino [3,2-G] quinolinones	1048
as anti-inflammatory	2031	cross-reactivity to other NRs	1050
as anti-oxidation	2031	medicinal chemistry of	1048
as promoter of bile salts formation	2032	pharmacology of	1050
as therapeutic agent	2023	2,3,4,14 -Tetrahydro-1 <i>H</i> -dibenzo[b,f]pyrido-[1,2-d]	
availability of	2022	[1,4]oxazepin-1-amines	1024
biosynthesis of	2022	cross-reactivity to other NRs	1025
inhibition of connexin 26 containing channels		medicinal chemistry of	1024
by	2035	pharmacology of	1025
cardiovascular activity of	2029	Tetrahydronaphthofuranones/tetrahydrobenzindolones .	1020
chemistry of	2021	cross-reactivity to other NRs	1021
deficiency of	2022	medicinal chemistry of	1020
in bone metablism	2034	pharmacology of	1021
in hepato-protection	2033	1,2,3,6-THP	555,556
in modulation of immune system	2035	oxidation reactions of	556
in retinal protection	2028	synthetic applications of	555
metabolism of	2022	Tetrahydropyridine (THP)	551,1018
modificiation of	2022	cross-reactivity to NRs	1019
muscular-activity of	2027	medicinal chemistry of	551,1017
other activities of	2035		

nomenclature of	551	protein inhibition by	2248
pharmacology of	551,554,1019	protein structure to function of	2245
via cyclization reactions	554	structure of	2241
via reduction of pyridinium ring	552		
Tetrahydroquinolines (THQS)	1093,1057	Thymidylate synthase inhibition	191
cross-reactivity to other NRs	1042,1057	consequences of.....	192
medicinal chemistry of	1039,1057	novel chemical strategies for.....	191
pharmacology of	1042,1057	role of 5FU pro-drugs.....	199
Tetrodotoxin	2101	role of antifolates.....	193
IR spectra of	2101	role of benzoquinazoline antifolates	197
TF/FVIIA complex	401	role of early TS-inhibitory antifolates.....	195
allyloxycarbonyl- <i>p</i> -amidinophenylalanines		role of FdUMP [N] oligodeoxynucleotides.....	199
against	408	role of FdUMP pro-drugs.....	198
arginine-based electrophilic analogues against ...	408	role of multi-targeted antifolates	197
benzenes against	409	role of nucleoside analogs.....	198
benzenesulfonamides against	412	strategies for.....	192
benzoxazinones against	414	Tin	2607
indolizidinones against	414	apoptosis by	2607
-ketothiazoles against	409		
naphtyl derivatives against	414	Tissue factor	397
natural/genetically engineered inhibitors of	403	angiogenesis	401
oxpyridines against	409	antagonists of	406
<i>p</i> -amidinophenyl-ureas/thioureas against	408	complex of	397
phenylacetamide against	408	exosite inhibitors of	406
phenylalanine against	408	focus of	397
pyrazinones against	409	in cancer	401
pyridones against	109	inhibitors of	397
pyrimidinones against	409	peptidomimetics of	408
structure of	401	recent advances in	397
TF/FVIIA modulators	401	small molecular weight inhibitors of	408
development of	401	synthetic peptides as modulators of activity of ...	406
in angiogenesis	401		
in cancer	401	Tissue inhibitor of matrix metalloproteinase	917
in haemostasis disorders	401	as prognostic/clinical indicators	920
Thalassaemia	2665, 2732	circulating type	920
antioxidants in	2733	impact of drug therapies	923
chelators in	2733	in myocardial remodelling	922
treatment of	2733	in unstable coronary artery disease	921
Thallium	2777	in unstable plaque	922
Thermolysin	351	variance/genetic polymorphisms of	921
structural studies of	351		
substrate selectivity of.....	351	Tissue oxygenation	833
Thiazolidinones	1064	and hypoxia	833
cross-reactivity to other NRs	1064	pO ₂ reporter molecules of	834
medicinal chemistry of	1064		
pharmacology of	1064	Tissue-selective PARP-1 inhibition	2380
Thiosemicarbazone iron chelators	2717	Tissue specific MR contrast agents	2798
Thiophenyl cyclo propyl sulfonamides	1029	Tumour necrosis factor- converting enzyme	
cross-reactivity to other NRs	1029	(TACE)	2963
medicinal chemistry of	1029	inhibitors of	2963,2969
pharmacology of	1029	-Tocopherol quinone (TQ)	2607
Thymidylate synthase	2241	Topo poisons.....	130
function of	2241	Toxins	2601
implication in drug discovery	2241	mechanism of	2601
novel inhibition strategies to	2255	structure-activity relationships of	2601
pathways of	2241		
pharmacogenetic of	2256	Transcription factor	691
pharmacogenomics of	2256	and androgen receptor	698
		and drug discovery	692
		and Egr-1	699
		and estrogen receptor	698
		and NFAT	698
		and p53	698

based therapeutic approaches in disease progression.....	695	recognized by T-cell receptor	1583
ChIP-array related methods for	694	structure of	1581
computational tools for	693	2,4,6-Trinitrotoluene (TNT)	2608
delivery of therapeutic agents of	692	formation of adrenochrome	2608
disease associations with	691	Triphenylmethanes	1029
drug targets for	698	cross-reactivity to other NRs	1030
effect of antioncogenic drugs	695	medicinal chemistry of	1029
in mood disorders	698	pharmacology of	1031
in neurological diseases	698	Triple helix-forming oligonucleotides.....	72
network/pathway modeling for	694	antigene strategy of.....	72
polymorphisms of	696	Triplex antisense technology	2199
rational drug design of	694	TS mRNA (antisensestrategy).....	200
role of chimeric	695	antisense targeting of.....	200
role of promoter	696	Tuberculosis (TB)	1873
therapeutics of	691	Tumor lymphangiogenesis	3043
Transferrin	2688,2714	animal models of	3046
structure of	2688	development of lymphatic vessels in	3443
transfusional iron overload in	2664	in human	3046
transport/uptake of	2714	pathways of	3050
Transferrin receptor 1	2714	role of lymphendothelial growth factors	3044
Transferrin receptor 2	2715	role of lymphendothelial transcription factors ...	3045
Transglutaminase	2357	role of sentinel lymph node	3050
as target for therapeutic interventions	2368	Tumor.....	319
in angiogenesis	2365	and host related factors	319
in atherosclerosis	2366	Tumor associated antigens (TAAs)	1485
in control of vascular modelling	2365	identification of	1485
in inflammation	2366	selection of	1485
in vascular biology	2362	Tumor blood volume	840
in vascular permeability	2366	Tumor cells.....	319
in wound healing	2365	accessibility of.....	319
perspectives for therapeutic interventions	2357	Tumor sensitivity.....	320
physiopathologic implications of	2357	to radiation.....	320
properties of	2362	Tumor size	319
role in cell death	2364	accessibility of.....	319
tumour biology of	2368	Tumor suppressor molecules	2720
vascular biology of	2357	cell cycle control by	2720
Translation inhibitors	1285	Type-1/type-2 cytokine	1537
Tricyclic androgen receptor modulators	1043	modulation by therapeutic peptides	1537
cross-reactivity to other NRs	1045	secretion patterns of	1537
medicinal chemistry of	1043	Tyrosine kinases	1254
pharmacology of	1045	Uptake pharmacophore	2393
Tricyclic azepines	1052	classical QSAR of	2398
cross-reactivity to other NRs	1053	3D-QSAR analysis of	2393
medicinal chemistry of	1052	of serotonin transporter	2393
pharmacology of	1053	Ureas 1051	
4-Trifluoromethyl-quinolin-2-ones	1056	cross-reactivity to other NRs	1052
cross-reactivity to other NRs	1057	medicinal chemistry of	1051
medicinal chemistry of	1056	pharmacology of	1052
pharmacology of	1057	Urinary steroid	1339
Triglyceride (TG)	1931	measurements in endocrine/psychiatric	
metabolism of	1932	diseases	1339
risk of CHD by	1931	Urocortins (Ucn)	1503
Trimethylamine-carboxyborane	1996		
Trimolecular complex MHC	1580		
antigen interactions of	1581		
polymorphism of	1581		

V3-CCR5/CXCR4 interaction	1563	crystal structure of	2499
Vaccine delivery	1490	crystallographic information of	2500
Vanadium	1182	developments of	2413
and reactive oxygen species	1183	discovery of	2539
as therapeutic agent	1184	isolation of	2413
in signaling pathways	1182	mechanistic studies of	2542
Venesection therapy	2668	miscellaneous	2461
VGLUT inhibitor	2044	mode of action of	2539
alkaloids as	2051	naturally-occurring	2413
amino acids as	2044	NMR techniques for structure assignment of	2481
anion channel/vacuolar ATPase blockers as	2051	optimization of	2539
conformationally-restricted amino acid analogs		structure elucidation of	2413,2499
as	2045	synthesis of	2447
azo dyes as	2046	with fused rings	2458
fatty acids as	2045	Xanthone core	2457
fluorescein derivatives as	2052	substituents into	2457
kynurenate analogues as	2049	Xanthone derivatives	2481,2517
kynurenate as	2049	antitumor activity of	2522
miscellaneous inhibitors of	2050	biological activities of	2517
protein inhibitors as	2051	cellular systems modulated by	2522
pyridines as	2049	enzyme systems modulated by	2520
quinolines as	2049	nuclear magnetic resonance spectroscopy to	
quinoline-2,4-dicarboxylic acids as	2050	study	2481
substituted amino acids as	2044	PKC modulation by	2526
sulfhydryl modifying agents as	2052	structure elucidation of	2481
Virus-mediated delivery	1843	Xanthonic tricyclic system	2452
adeno-associated viruses (AAV) based	1843	new approaches to synthesis of	2452
adenoviruses based	1843	Xanthonolignoids	2441,2488
alphavirus based	1844	Xantohumol	724
baculovirus based	1844	Yeast extract	3085
herpes simplex viruses (HSV) based	1844	blood-pressure lowering effect of	3085
lentiviruses based	1844	in bioactive peptides	3085
retroviruses based	1843	in hypertensive model	3085
Water-soluble PARP-1 inhibitors	2377	Yeast pheromone signaling pathway	963
Xanthines (LXR)	1070	as bioassay for GPCR-ligand screening	963
medicinal chemistry of	1070	Zinc	1197,2753,2607
pharmacology of	1070	antioxidant therapy for	2756
Xanthones	2413,2447,2481,2499,2517,2539	chelation therapy for	2753,2755
antitumor activity of	2522	metabolism of	2754
as antileishmanial agents	2548	metallothionein up-regulation of	2755
as antimalarial agents	2539,2540	neuronal toxicity of	2754
basic skeleton of	2499	pancreatic toxicity of	2754
biological activities of	2493	therapeutic approaches to toxicity of	2755
calculated NMR chemical shifts of	2493	toxicity of	2753,2754
classical methods for synthesis of	2447		
classification of	2413		
correlation between heme affinity/antimalarial			
potency of	2543		